

Weekly

June 1, 2007 / Vol. 56 / No. 21

## Multistate Outbreak of Salmonella Serotype Tennessee Infections Associated with Peanut Butter — United States, 2006–2007

In November 2006, public health officials at CDC and state health departments detected a substantial increase in the reported incidence of isolates of Salmonella serotype Tennessee. In a multistate case-control study conducted during February 5-13, 2007, illness was strongly associated with consumption of either of two brands (Peter Pan or Great Value) of peanut butter produced at the same plant. Based on these findings, the plant ceased production and recalled both products on February 14, 2007. The outbreak strain of Salmonella Tennessee subsequently was isolated from several opened and unopened jars of Peter Pan and Great Value peanut butter and from two environmental samples obtained from the plant. New case reports decreased substantially after the product recall (Figure 1). As of May 22, 2007, a total of 628 persons infected with an outbreak strain of Salmonella serotype Tennessee had been reported from 47 states since August 1,





\* Cases with outbreak-associated pulsed-field gel electrophoresis pattern and for which date of symptom onset was available. 2006 (Figure 2). Local and state public health officials in multiple states, with assistance from CDC and the Food and Drug Administration (FDA), are continuing to investigate this outbreak caused by peanut butter, a new food source for salmonellosis in the United States. All remaining jars of Peter Pan or Great Value peanut butter with a product code beginning with 2111 should be discarded.

Public health officials in PulseNet (the molecular subtyping network for foodborne disease surveillance) and OutbreakNet

FIGURE 2. Number of confirmed cases (N = 628)\* of Salmonella Tennessee infection associated with consumption of peanut butter, by state — United States, August 1, 2006–May 22, 2007



\*Cases with outbreak-associated pulsed-field gel electrophoresis pattern.

#### INSIDE

- 524 Sunburn Prevalence Among Adults United States, 1999, 2003, and 2004
- 529 Characteristics and Health of Caregivers and Care Recipients — North Carolina, 2005
- 532 Acanthamoeba Keratitis Multiple States, 2005–2007
- 535 QuickStats

DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

**Suggested Citation:** Centers for Disease Control and Prevention. [Article title]. MMWR 2007;56:[inclusive page numbers].

#### **Centers for Disease Control and Prevention**

Julie L. Gerberding, MD, MPH Director Tanja Popovic, MD, PhD Chief Science Officer

James W. Stephens, PhD (Acting) Associate Director for Science Steven L. Solomon, MD Director, Coordinating Center for Health Information and Service Jay M. Bernhardt, PhD, MPH Director, National Center for Health Marketing B. Kathleen Skipper, MA (Acting) Director, Division of Health Information Dissemination (Proposed)

#### **Editorial and Production Staff**

Frederic E. Shaw, MD, JD Editor, MMWR Series Myron G. Schultz, DVM, MD (Acting) Deputy Editor, MMWR Series Suzanne M. Hewitt, MPA Managing Editor, MMWR Series Douglas W. Weatherwax Lead Technical Writer-Editor Catherine H. Bricker, MS Jude C. Rutledge Writers-Editors Beverly J. Holland Lead Visual Information Specialist Lynda G. Cupell Malbea A. LaPete Visual Information Specialists Quang M. Doan, MBA Erica R. Shaver Information Technology Specialists

#### Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ Margaret A. Hamburg, MD, Washington, DC King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Stanley A. Plotkin, MD, Doylestown, PA Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

(the network of public health epidemiologists who investigate foodborne illnesses nationwide) have been investigating this outbreak and attempting to identify the mechanism of initial contamination. The investigation began in November 2006, when public health officials in PulseNet noted a substantial increase in the number of isolates of the outbreak strain of *Salmonella* serotype Tennessee; throughout 2005 and most of 2006, these isolates were reported to PulseNet at a rate of one to five per month, whereas in October 2006, 30 isolates were reported. Pulsed-field gel electrophoresis (PFGE) patterns of *Salmonella* Tennessee strains isolated from patients were uploaded from state health department databases to CDC databases. Three closely related patterns\* were determined to be associated with this outbreak.

A case was defined as infection with *Salmonella* Tennessee with a PFGE pattern matching one of the three outbreak patterns in a person residing in the United States with symptom onset on or after August 1, 2006 (or, if onset date unknown, *Salmonella* Tennessee isolated on or after August 1, 2006). The median age of patients was 52 years (range: 2 months–95 years); 73% were female. Symptoms of infection included diarrhea (72%), abdominal cramps (65%), fever (43%), and dysuria (45%). Symptom onset dates were known for 481 of 628 patients and ranged from August 1, 2006 to April 23, 2007 (Figure 1). Twenty percent of patients were hospitalized; no deaths were attributed to *Salmonella* infection. Sixtyone percent of isolates were from stool specimens, 35% from urine specimens, and 4% from other specimens.

The initial investigation indicated that cases were not clustered geographically, and patient interviews conducted during November–December 2006 by state and local officials from OutbreakNet did not reveal a common food exposure. Officials in multiple states then interviewed 26 patients in January 2007 using a standard food-consumption survey instrument of approximately 200 items. Interviews indicated that 48% of the patients had eaten turkey (excluding delicatessen-sliced turkey) and 85% had eaten peanut butter during the week before illness onset, higher proportions than would be expected from food-consumption surveys of the U.S. population (1).

In February 2007, a case-control study with 65 patients and 124 controls was conducted to identify the food item associated with illness; the majority of interviews were completed by state and local health departments and were coordinated by CDC. For the study, a case was defined as infection with the outbreak strain of *Salmonella* Tennessee in a person aged  $\geq$ 18 years with a history of diarrhea. Controls were well adults

<sup>\*</sup> CDC PulseNet patterns JNXX01.0010, JNXX01.0011, and JNXX01.0026.

from the patient's community who were matched by geographic location. Controls were identified using a reverse online telephone directory that when given an address provided telephone numbers for residences in the same extended neighborhood as the patients. The median ages for the patients and controls were 53 and 58 years, respectively. Patients were more likely than controls to have eaten peanut butter (81% versus 65%, matched odds ratio [mOR] = 1.9, 95% confidence interval [CI] = 0.8–5.2), to have eaten peanut butter more than once a week (66% versus 40%, mOR = 3.5, CI = 1.4– 9.9), and to have eaten either Peter Pan or Great Value peanut butter (67% versus 13%, mOR = 10.9, CI = 3.8–43.0). Neither the consumption of other peanut butter brands nor consumption of turkey products was associated with illness.

Epidemiologic data suggesting Peter Pan brands of peanut butter as the possible source of the outbreak were provided to FDA officials on February 13, 2007. The following day, FDA issued a health alert to consumers indicating that they should not eat Peter Pan or Great Value peanut butter with a product code beginning with 2111, both of which were manufactured in a single facility in Georgia operated by ConAgra Foods. ConAgra Foods voluntarily recalled the products, destroyed existing products in their possession, and temporarily halted production pending further investigation.

New case reports decreased substantially after the February 14 recall (Figure 1). Investigation of the cases is ongoing to determine whether persons are still eating peanut butter from contaminated lots.

Subsequent laboratory testing of leftover peanut butter from patients was performed at state public health laboratories and CDC. Salmonella Tennessee with a PFGE pattern matching one of the outbreak strains was isolated from 21 opened and unopened peanut butter jars with production dates ranging from July 2006 to December 2006. These jars were collected from patients in 13 states (Arkansas, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Minnesota, New York, Oklahoma, Pennsylvania, South Carolina, and Tennessee); two of the PFGE strains were isolated from these peanut butter samples. FDA isolated Salmonella Tennessee from 13 unopened jars of Peter Pan and Great Value peanut butter with production dates ranging from August 2006 to January 2007 and from two plant environmental samples. Peanut butter from the Georgia plant was exported to 70 countries. No confirmed cases linked to this outbreak have been reported from other countries, although several possibly related cases have been investigated.

The source of the peanut butter contamination is unknown. FDA is investigating the plant operations, including heating temperatures, to determine the mechanism. **Reported by:** Salmonella *Tennessee Outbreak Investigation Team. Local* and state health departments. Div of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, CDC.

Editorial Note: Approximately 2,500 Salmonella serotypes can cause salmonellosis, an illness characterized by diarrhea, fever, and abdominal cramps, typically 12-72 hours after infection (2). Salmonella Tennessee infections are rare, and the source of most of these infections is unknown. An average of 52 Salmonella Tennessee cases were reported to the National Salmonella Surveillance System<sup>†</sup> each year during 1995-2004, representing 0.1% of all reported Salmonella strains (3). Only one other outbreak of Salmonella Tennessee infection with an identified food source, contaminated powdered milk, has been reported to CDC (4). In addition to causing gastrointestinal symptoms, certain serotypes, including Salmonella Tennessee, are more likely than other serotypes to infect the urinary tract. The percentage of patient Salmonella Tennessee isolates from urine specimens increased from 15% during 1995–2004 to 27% during 2005–2006. Because urinary tract infections are more common among females, the high proportion of isolates from urine in this outbreak might explain the high percentage of identified cases among females (3,5).

This is the first reported outbreak of a foodborne illness caused by peanut butter consumption in the United States. Outside the United States, one outbreak implicating peanut butter, caused by *Salmonella* serotype Mbandaka, was reported from Australia in 1996 (6). In addition, an outbreak of *Salmonella* serotype Agona infection in four countries was associated with consumption of a peanut-butter–coated snack produced in Israel (7,8).

Peanuts can become contaminated with salmonellae during growth, harvest, or storage, and the organisms are able to survive high temperatures in a high-fat, low-water–activity environment (9). Peanut butter provides such an environment, and although it typically undergoes heat treatment to temperatures >158°F (>70°C), such heating might not always eliminate salmonellae (10). In addition, after heat treatment, peanut butter that is being processed might be contaminated by salmonellae that are introduced into the production environment on raw peanuts or another source (e.g., animals in the production plant, salmonellae brought into the plant on containers or humans from the outside environment, or other ingredients used to make peanut butter).

<sup>&</sup>lt;sup>†</sup> The National *Salmonella* Surveillance System collects information on serotypes of *Salmonella* isolates reported through the Public Health Laboratory Information System, an electronic reporting system. Additional information is available at http://www.cdc.gov/ncidod/dbmd/phlisdata/salmonella.htm.

This outbreak demonstrates the potential for widespread illness from a broadly distributed contaminated product, one that has not been previously implicated in a foodborne illness outbreak in the United States. In addition, the outbreak demonstrates that processed food can become contaminated even when the production process includes a heat-treatment step, underscoring the need for effective preventive controls in foodprocessing plants to prevent contamination.

Certain consumers might still be eating peanut butter from contaminated lots. All remaining jars of Peter Pan and Great Value peanut butter with a product code beginning with 2111 should be discarded.

#### References

- 1. CDC. Foodborne diseases active surveillance network (FoodNet): population survey atlas of exposures, 2002. Atlanta, GA: CDC; 2004. Available at http://www.cdc.gov/foodnet/surveys/pop/2002/2002atlas.pdf.
- Brenner FW, Villar RG, Angulo FJ, Tauxe RV, Swaminathan B. Salmonella nomenclature. J Clin Microbiol 2000;38:2465–7.
- CDC. Salmonella surveillance summary, 2004. Atlanta, GA: US Department of Health and Human Services, CDC; 2006. Available at http://www.cdc.gov/ncidod/dbmd/phlisdata/salmonella.htm.
- CDC. Salmonella serotype Tennessee in powdered milk products and infant formula—Canada and the United States, 1993. MMWR 1993; 42:501–19.
- Sivapalasingam, S, Hoekstra RM, McQuiston JR, et al. Salmonella bacteriuria: an increasing entity in elderly women in the United States. Epidemiol Infect 2004;132:897–902.
- Scheil W, Cameron S, Dalton C, Murray C, Wilson D. A South Australian *Salmonella* Mbandaka outbreak investigation using a database to select controls. Aust N Z J Public Health 1998;22:536–9.
- Killalea D, Ward LR, de Roberts D, et al. International epidemiological and microbiological study of outbreak of *Salmonella agona* infection from a ready-to-eat savoury snack—I: England and Wales and the United States. BMJ 1996;313:1105–7.
- Shohat T, Green MS, Marom D, et al. International epidemiological and microbiological study of outbreak of *Salmonella agona* infection from a ready-to-eat savoury snack—II: Israel. BMJ 1996;313:1107–9.
- 9. Mattick KL, Jorgensen F, Legan JD, Lappin-Scott HM, Humphrey TJ. Habituation of *Salmonella spp.* at reduced water activity and its effect on heat tolerance. Appl Environ Microbiol 2001;66:4921–5.
- Shachar D, Yaron S. Heat tolerance of *Salmonella enterica* serovars Agona, Enteritidis, and Typhimurium in peanut butter. J Food Protect 2006;69:2687–91.

## Sunburn Prevalence Among Adults — United States, 1999, 2003, and 2004

Episodic acute overexposure to ultraviolet (UV) radiation (i.e., sunburn) is an important risk factor for two types of skin cancer: basal cell carcinoma and melanoma. Melanoma is the most lethal type of skin cancer. In 2003, a total of 45,625 new cases of melanoma were diagnosed in the United States, and 7,818 persons died from the disease (1). A meta-analysis of 57 studies indicated that the relative risk for melanoma among persons with sunburn history compared with those without sunburn history was 2.03 (95% confidence interval [CI] = 1.73-2.37) (2). Monitoring sunburn prevalence with population-based surveys allows an estimate of compliance with sun-protection behaviors, assessments of risk for developing skin cancer, and measurement of the success of prevention programs (3). To evaluate trends in sunburn prevalence among U.S. adults, CDC analyzed cross-sectional data from the 1999, 2003, and 2004 Behavioral Risk Factor Surveillance System (BRFSS) surveys. This report describes the results of that analysis, which indicated that sunburn prevalence among all adults increased from 31.8% in 1999 to 33.7% in 2004. Further research is needed to determine which interventions will best improve sunprotection behaviors among the public.

BRFSS is a state-based, random-digit-dialed telephone survey of the noninstitutionalized, U.S. civilian population aged ≥18 years. Questions are administered in English and Spanish, as necessary. Two questions related to self-reported sunburn experiences were used in the core section (i.e., the survey questions administered in all states) of the 1999, 2003, and 2004 questionnaires. The first question was presented as follows: "The next question is about sunburns, including any time that even a small part of your skin was red for more than 12 hours. Have you had a sunburn within the past 12 months?" Persons who responded "yes" were then asked, "Including times when even a small part of your skin was red for more than 12 hours, how many sunburns have you had within the past 12 months?" Excluded from the analysis were respondents who had missing answers, refused to answer, or answered "don't know" on the questionnaire. In 1999, a total of 156,095 persons responded, of whom 2,778 (1.8%) were excluded; in 2003, a total of 256,457 persons responded, of whom 3,478 (1.4%) were excluded; and in 2004, a total of 296,027 persons responded, of whom 906 (0.3%) were excluded. The median state response rate, based on Council of American Survey and Research Organizations guidelines, was 55.2% in 1999, 53.2% in 2003, and 52.7% in 2004. Information on each respondent's age, race/ethnicity, and sex and other demographic data also were collected in BRFSS.

Weighted prevalence of sunburn by race/ethnicity, sex, and state was calculated for each year and for all survey years combined. Data were weighted to the sex, racial/ethnic, and age distribution of the adult population of each state using intercensal estimates. To allow comparison among survey years, stratified BRFSS data were age adjusted to the 2000 U.S. standard population using six age groups: 18–24 years, 25–34 years, 35–44 years, 45–54 years, 55–64 years, and  $\geq$ 65 years. Differences in prevalence were considered statistically significant if CIs did not overlap.

Estimated sunburn prevalence among all adults ranged from 31.8% in 1999 to 33.7% in 2004 (Table 1). Men had a higher prevalence of sunburn than women in all three survey years (35.8% versus 28.0% in 1999, 37.0% versus 30.2% in 2003, and 37.0% versus 30.3% in 2004). Sunburn prevalence increased from 1999 to 2004 among non-Hispanic white women (from 35.3% to 39.6%) and non-Hispanic white men (from 44.1% to 46.9%) (Table 1). Sunburn also was reported among racial/ethnic groups traditionally considered at lower risk for sunburn or skin cancer, such as Hispanic blacks (12.4% among men and 9.5% among women in 2004), Asians/ Pacific Islanders (16.2% among men and 16.1% among women in 2004), and American Indians/Alaska Natives (30.4% among men and 21.5% among women in 2004). Non-Hispanic blacks had low prevalence of sunburn (5.8% among men and women in 2004) (Table 1).

Among adults who reported sunburn during the preceding year, 20.7% reported four or more sunburns (all survey years combined). Non-Hispanics whites and American Indians/ Alaska Natives had the highest proportion of respondents with four or more sunburns during the preceding year (21.2% and 19.6%, respectively) (Table 2).

In 2004, a total of 20 states\* reported a statistically significant increase in sunburn prevalence among whites, compared with 1999; four states (Indiana, Iowa, Kentucky, and Louisiana) reported a significant decrease in sunburn prevalence. The lowest reported sunburn prevalence among whites during any of the three survey years was 25.7% (Arizona, 1999), and the highest was 51.3% (Utah, 2003) (Table 3 and Figure).

**Reported by:** M Saraiya, MD, Div of Cancer Prevention and Control; L Balluz, ScD, XJ Wen, MD, Div of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion; DA Joseph, MD, EIS Officer, CDC.

Editorial Note: For all three survey years, approximately one third of the U.S. adult population had at least one sunburn during the preceding year. Of those who had at least one sunburn during the preceding year, two thirds had more than one sunburn. These findings are consistent with previous similar analyses and suggest that a substantial segment of the adult population is not consistently practicing sunprotection behaviors (3). CDC recommends the following sunprotection behaviors: wearing a wide-brimmed hat, covering up while in the sun, seeking shade, wearing wrap-around sunglasses, avoiding the sun during the hours of 10 a.m. to 4 p.m., and using sunscreen with a sun protection factor [SPF] of 15 or higher.<sup>†</sup>

Sunburn prevalence in racial/ethnic minority groups has not been well characterized previously. Skin-cancer prevention messages traditionally have been targeted toward white audiences because whites are at least 10 times more likely to

		1999	:	2003	2004		
Characteristic	%	(95% CI†)	%	(95% CI)	%	(95% CI)	
Men							
White, non-Hispanic	44.1	(43.5-44.8)	46.5 <sup>§</sup>	(45.9–47.1)	46.9 <sup>§</sup>	(46.4–47.5)	
White, Hispanic	21.6	(19.4-23.8)	24.8	(22.0-27.7)	20.1	(18.8–23.3)	
Black, non-Hispanic	5.3	(4.3-6.4)	4.6	(3.7-5.6)	5.8	(4.7-7.0)	
Black, Hispanic	14.3	(10.1-19.8)	12.3	(8.4-17.8)	12.4	(8.4–17.5)	
Asian/Pacific Islander	18.0	(14.5-22.1)	18.6	(15.5-22.1)	16.2	(13.6-19.2)	
American Indian/Alaska Native	27.4	(23.0-32.4)	25.9	(22.1-30.0)	30.4	(26.3-34.8)	
Total	35.8	(35.2–36.3)	37.0 <sup>§</sup>	(36.5–37.6)	37.0 <sup>§</sup>	(36.4–37.6)	
Women							
White, non-Hispanic	35.3	(34.8–35.8)	38.7 <sup>§</sup>	(38.3-39.2)	39.6 <sup>§</sup>	(39.1–40.0)	
White, Hispanic	17.2	(15.6–19.0)	19.7	(17.9–21.6)	17.2	(15.8–18.8)	
Black, non-Hispanic	5.1	(4.5–5.9)	5.7	(5.1–6.4)	5.8	(5.2–6.5)	
Black, Hispanic	8.3	(5.7–12.0)	13.5	(8.7–20.3)	9.5	(6.7–13.2)	
Asian/Pacific Islander	11.0	(8.9–13.6)	14.4	(12.3–16.8)	16.1	(12.9–19.9)	
American Indian/Alaska Native	23.5	(19.7–27.8)	23.3	(19.9–27.0)	21.5	(18.6–24.7)	
Total	28.0	(27.5–28.4)	30.3 <sup>§</sup>	(29.9–30.7)	30.3 <sup>§</sup>	(29.9–30.7)	
Total	31.8	(31.4–32.2)	33.6 <sup>§</sup>	(33.2–33.9)	33.7 <sup>§</sup>	(33.4–34.1)	

TABLE 1. Estimated percentage of respondents aged  $\geq$ 18 years who reported having had at least one sunburn during the preceding year, by sex and race/ethnicity — Behavioral Risk Factor Surveillance System, United States, 1999, 2003, and 2004\*

\*Age adjusted to the 2000 U.S. standard population.

<sup>†</sup>Confidence interval.

<sup>9</sup>Statistically significant difference compared with 1999. Differences were considered statistically significant if CIs did not overlap.

<sup>\*</sup>Alaska, Arizona, Connecticut, Florida, Idaho, Kansas, Maine, Massachusetts, Minnesota, Montana, Nebraska, New Jersey, New York, North Dakota, Oklahoma, Pennsylvania, South Carolina, Tennessee, Vermont, and Washington.

<sup>&</sup>lt;sup>†</sup> Additional information available at http://www.cdc.gov/cancer/skin/basic\_info/ howto.htm.

TABLE 2. Estimated percentage of respondents aged  $\geq$ 18 years who reported having had at least one sunburn during the preceding year, by number of sunburns and race/ethnicity — Behavioral Risk Factor Surveillance System, United States, 1999, 2003, and 2004 (all survey years combined)\*

	No. of sunburns											
		1		2		3	≥4					
Race/Ethnicity <sup>†</sup>	%	(95% Cl <sup>§</sup> )	%	(95% CI)	%	(95% CI)	%	(95% CI)				
White, non-Hispanic	35.6	(35.2–36.2)	28.3	(27.9–28.7)	14.9	(14.6–15.2)	21.2	(20.8–21.5)				
White, Hispanic	45.6	(42.2-49.1)	23.4	(20.8-26.1)	11.9	(10.3–13.7)	19.1	(17.0–21.5)				
Black, non-Hispanic	50.4	(46.4–54.4)	25.5	(21.5–28.0)	11.8	(9.7–14.3)	12.3	(10.3–14.6)				
Asian/Pacific Islander	53.3	(48.1-58.5)	22.1	(18.6-25.9)	9.1	(7.2–11.4)	15.5	(12.0-19.8)				
American Indian/Alaska Native	44.2	(39.8–48.6)	22.5	(19.2–26.1)	13.8	(10.9–17.4)	19.6	(16.7–22.9)				
Total	36.9	(36.5–37.4)	27.8	(27.4–28.1)	14.6	(14.3–14.8)	20.7	(20.4–21.1)				

\*Age adjusted to the 2000 U.S. standard population.

<sup>+</sup> Hispanic blacks excluded from analysis because of small sample size.

§ Confidence interval.

develop melanoma than racial/ethnic minorities, although racial/ethnic minority populations are more likely to have more advanced disease diagnosed and to have lower 5-year survival rates (4,5). However, the findings in this report indicate that substantial portions of the Hispanic, Asian/Pacific Islander, and American Indian/Alaska Native populations acquired sunburns. Racial/ethnic groups with darker skin (higher melanin content) have a lower incidence of skin cancer, which is attributed, in part, to the inherent sun protection provided by melanin (5). However, race/ethnicity is a poor proxy for skin cancer risk because persons in racial/ethnic minority groups might have individual risk factors for skin cancer (e.g., lighter skin color; skin that burns, freckles, or reddens easily in the sun; or personal or family history of skin cancer) and might not benefit from the protective effects of melanin. In a study of adolescents aged 11-18 years, 21.7% of black respondents who reported having had a sunburn reported severe sunburn with blisters or peeling after 1 hour of exposure to sun during the summer (6).

The results of this analysis also indicated that men had a higher prevalence of sunburn than women in most of the racial/ ethnic groups surveyed. This finding might be attributed to different sun-protection behaviors or different sun-exposure conditions between men and women, (e.g., differences in leisure or work activities). In addition, women might be more concerned about the cosmetic effect of long-term sun exposure (e.g., wrinkling of the skin and the appearance of age spots) and thus might be more likely to avoid sun exposure, use makeup with sunscreen, or practice sun-protection behaviors (7). In 2003, white men had a higher melanoma incidence and mortality than white women (22.7 versus 15.1 and 4.4 versus 2.0 per 100,000 population, respectively) (1).

None of the states with sunburn prevalence among whites greater than 45% were traditional "sunbelt" states. Persons living in the northern states might use fewer precautions during the first sunny days after winter or might travel to other locations where they acquire sunburns (3). Previous analyses have demonstrated that states with lower UV radiation (i.e., those in higher latitudes) have had more rapid increases in melanoma incidence than states with higher UV radiation (8).

The findings in this report are subject to at least six limitations. First, the BRFSS survey is a telephone survey, and results obtained might not be generalizable to U.S adults without landline telephones. Second, responses are selfreported and therefore subject to recall bias. Third, the BRFSS survey does not contain questions regarding skin type or sun-protection behaviors, so this information cannot be correlated to sunburns. Fourth, this analysis was a crosssectional study, and individual sunburn patterns could not be followed over time. Fifth, the source of UV exposure (sun or artificial source) was not provided. Finally, the U.S. states in which respondents actually acquired their sunburns were unknown.

Sunburn prevalence among U.S. adults increased from 1999 to 2004. Several reasons might account for these increases. For example, the public might be receiving conflicting or confusing messages about what constitutes the best sunprotection behaviors. A review of 20 Internet sites about skin cancer prevention revealed inconsistent advice regarding a safe amount of sun exposure, times of day to avoid the sun, how many sunburns increase the risk for skin cancer, and the best types of clothing to use for sun protection (9). That review noted that only three recommendations were common to all 20 Internet sites: wearing broad-brimmed hats, wearing sunglasses, and using sunscreen with an SPF of 15 or higher (9). In addition, certain segments of the public might view the purported benefits of sun exposure (e.g., tanned skin or elevated mood) as outweighing the risk for skin cancer or might not be concerned about the risks of overexposure to the sun (9).

TABLE 3. Estimated percentage of white* respondents aged ≥18 years who reported having had at least one sunburn during the
preceding year, by state/area — Behavioral Risk Factor Surveillance System, United States, 1999, 2003, and 2004 <sup>†</sup>

	1999		2	2003	2004		
State/Area	%	(95% CI§)	%	(95% CI)	%	(95% CI)	
Alabama	39.6	(37.0-42.1)	39.7	(37.5–41.9)	39.6	(37.4–41.8)	
Alaska	27.8	(24.7–30.9)	32.6	(29.6–35.5)	34.1 <sup>¶</sup>	(31.1–37.0)	
Arizona	25.7	(22.1–29.2)	39.5 <sup>¶</sup>	(36.5–42.5)	42.1 <sup>¶</sup>	(40.0–45.2)	
Arkansas	42.0	(40.0–44.0)	41.8	(40.0–43.6)	42.9	(41.1–44.8)	
California	34.1	(32.5–35.8)	36.8	(35.0–38.6)	34.8	(33.0–36.6)	
Colorado	45.8	(43.4–48.1)	46.6	(44.9–48.4)	45.1	(43.3–46.8)	
Connecticut	33.3	(30.1–35.6)	40.7 <sup>¶</sup>	(39.1–42.3)	43.1 <sup>¶</sup>	(41.4–44.7)	
Delaware	43.6	(40.8–46.5)	33.5 <sup>¶</sup>	(31.3–35.7)	41.4	(39.1–43.6)	
District of Columbia	42.8	(37.5–48.1)	41.3	(38.1–44.5)	40.1	(37.4–42.8)	
Florida	33.4	(31.7–35.1)	36.8	(34.4–39.2)	37.7 <sup>¶</sup>	(35.7–39.6)	
Georgia	36.3	(33.8–38.8)	40.7 <sup>¶</sup>	(38.9–42.5)	39.2	(37.1–41.3)	
Hawaii	44.8	(39.8–49.8)	42.3	(39.6–44.9)	**	**	
Idaho	45.4	(43.8–46.9)	49.3 <sup>¶</sup>	(47.7–50.9)	48.5 <sup>¶</sup>	(47.0-50.1)	
Illinois	44.0	(40.1–47.1)	40.8	(38.5–43.1)	41.7	(39.8–43.7)	
Indiana	48.1	(44.8–51.4)	44.9	(43.4–46.4)	43.3 <sup>¶</sup>	(41.8–44.6)	
lowa	49.0	(47.1–50.8)	43.5 <sup>¶</sup>	(41.5–45.1)	43.6 <sup>¶</sup>	(42.0–45.2)	
Kansas	34.2	(32.5–35.9)	41.3 <sup>¶</sup>	(39.6–43.0)	41.4 <sup>¶</sup>	(40.2–42.6)	
Kentucky	30.7	(29.2–32.2)	28.0	(26.3–29.7)	27.0 <sup>¶</sup>	(25.2–28.8)	
Louisiana	35.2	(32.3–38.1)	31.0	(29.2–32.7)	30.5 <sup>¶</sup>	(29.1–31.9)	
Maine	37.0	(34.3–39.5)	42.8 <sup>¶</sup>	(40.6–44.9)	42.6 <sup>¶</sup>	(40.6–44.5)	
Maryland	41.4	(39.2–43.6)	41.4	(39.4–43.4)	43.9	(41.8–46.0)	
Massachusetts	35.2	(33.4–36.9)	41.0 <sup>¶</sup>	(39.5–42.6)	42.6 <sup>¶</sup>	(41.1–44.2)	
Michigan	47.6	(45.5–49.8)	47.9	(45.9–49.8)	45.6	(43.9–47.3)	
Minnesota	40.0	(38.6–41.4)	49.2 <sup>¶</sup>	(47.5–50.9)	48.7 <sup>¶</sup>	(46.9–50.4)	
Mississippi	39.9	(37.4–42.4)	42.4	(40.4–44.3)	40.5	(38.6–42.4)	
Missouri	42.9	(40.8–45.0)	45.9	(43.7–48.1)	45.2	(43.2–47.2)	
Montana	38.8	(36.3–41.2)	47.6 <sup>¶</sup>	(45.4–48.1)	44.1 <sup>¶</sup>	(42.2–45.9)	
Nebraska	43.1	(41.1–45.1)	46.3	(44.7–47.8)	46.9 <sup>¶</sup>	(45.5–48.3)	
Nevada	40.9	(37.8–44.1)	39.2	(36.6–41.2)	38.3	(35.4–41.4)	
New Hampshire	41.7	(38.8–44.6)	42.8	(41.2–44.4)	43.8	(42.2–45.5)	
New Jersey	32.8	(30.5–35.1)	39.0 <sup>¶</sup>	(37.8–40.3)	40.2 <sup>¶</sup>	(38.9–41.5)	
New Mexico	38.6	(36.6–40.7)	38.8	(37.0–40.6)	41.3	(39.6–43.0)	
New York	30.3	(28.1–32.5)	39.7 <sup>¶</sup>	(38.0–41.4)	40.2 <sup>¶</sup>	(38.5–42.0)	
North Carolina	30.9	(28.5–33.4)	28.1	(26.4–29.8)	28.1	(27.0–29.3)	
North Dakota	38.3	(36.0-40.6)	45.6 <sup>¶</sup>	(43.6–47.6)	46.4 <sup>¶</sup>	(44.5–48.3)	
Ohio	39.1	(36.1–42.1)	42.4	(40.3–44.5)	43.4	(41.0–45.9)	
Oklahoma	30.2	(28.2–32.3)	41.9 <sup>¶</sup>	(40.4–43.3)	41.5 <sup>¶</sup>	(40.0–43.0)	
Oregon	41.3	(38.7–43.8)	42.1	(40.3-43.9)	43.6	(41.9–45.2)	
Pennsylvania	36.5	(34.8-38.4)	43.8 <sup>¶</sup>	(41.9-45.7)	42.7 <sup>¶</sup>	(41.1-44.2)	
Rhode Island	35.0	(33.4–36.8)	38.5	(36.6-40.5)	38.7	(36.7–40.7)	
South Carolina	32.7	(30.7–34.7)	42.8 <sup>¶</sup>	(41.2–44.4)	41.6 <sup>¶</sup>	(40.1–43.2)	
South Dakota	45.9	(44.2-47.5)	47.2	(45.7-48.8)	46.1	(44.6-47.7)	
Tennessee	26.6	(24.7–28.5)	30.7	(28.4–33.0)	32.6 <sup>¶</sup>	(30.4-34.7)	
Texas	36.6	(34.8–38.3)	38.1	(36.6–39.7)	37.7	(36.0–39.3)	
Utah	46.1	(43.9–48.3)	51.3 <sup>¶</sup>	(49.3–53.1)	49.9	(48.3–51.5)	
Vermont	39.1	(37.3-40.9)	45.7 <sup>¶</sup>	(44.0-47.4)	47.1 <sup>¶</sup>	(45.8-48.5)	
Virginia	40.5	(37.8-43.2)	41.5	(39.5-43.4)	42.9	(40.8-44.9)	
Washington	39.6	(37.6-41.6)	38.3	(37.3-39.2)	43.6 <sup>¶</sup>	(42.7-44.6)	
West Virginia	34.8	(32.8–36.8)	41.5 <sup>¶</sup>	(39.5–43.4)	38.0	(36.1–40.0)	
Wisconsin	51.4	(49.1–53.7)	49.3	(47.5-51.2)	48.6	(46.9-50.4)	
Wyoming	48.4	(46.4–50.5)	49.5	(47.8–51.2)	48.3	(46.6–50.0)	
Guam	**	**	50.6	(41.3–59.8)	**	**	
Puerto Rico	12.8	(11.2–14.7)	11.8	(10.0–13.6)	14.2	(12.4–16.0)	
U.S. Virgin Islands	**	**	46.5	(38.1–54.8)	50.1	(45.0–55.3)	
United States	37.0	(36.5–37.4)	40.0¶	(39.6–40.4)	39.9 <sup>¶</sup>	(39.5–40.3)	

\* Includes Hispanic whites.
<sup>†</sup> Age adjusted to the 2000 U.S. standard population.
§ Confidence interval.
<sup>¶</sup> Statistically significant difference compared with 1999. Differences were considered statistically significant if CIs did not overlap.
\*\* Did not participate in survey.

1999 DC 🗆 🛛 Guạm ⊠ USVI<sup>¶</sup> 2003 DC Guam USVI 2004 DC S Guam 🗆 PR USVI □ 1.0%-35.0% 35.1%-40.0% 40.1%-45.0% >45.1% Did not participate in survey

Includes Hispanic whites.

<sup>T</sup> Age adjusted to the 2000 U.S. standard population.

<sup>8</sup>Puerto Rico.

<sup>¶</sup>U.S. Virgin Islands.

Further research is needed to determine which public health interventions will improve sun-protection behaviors. The Guide to Community Preventive Services review of interventions to prevent skin cancer found sufficient evidence to warrant recommending educational and policy interventions for children in primary schools and for adults in recreational and tourism settings. However, evidence to warrant recommending other interventions, such as mass media campaigns and interventions in secondary schools, was insufficient (10). Future research on interventions to improve sun-protection behaviors should assess 1) the incorporation of messages that emphasize that sun-protection behaviors are readily implemented, and 2) the standardization of messages to eliminate confusing or conflicting advice. Public health messages specific to various racial/ethnic groups, certain subgroups (e.g., persons with lighter skin and men), and other populations at high risk (e.g., those with a personal or family history of skin cancer) need to be developed to emphasize that these populations also are susceptible to the harmful effects of the sun. Greater knowledge of interventions that will increase the proportion of persons who practice sun-protection behaviors is important for reducing sunburn prevalence and ultimately reducing skin cancer incidence and mortality. Continued surveillance of sunburn prevalence is necessary for evaluating the effectiveness of both current and new interventions.

#### References

- 1. US Cancer Statistics Working Group. United States cancer statistics: 1999–2003 incidence and mortality web based report. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2006. Available at http://www.cdc.gov/uscs.
- Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005;41:45–60.
- Saraiya M, Hall I, Uhler RJ. Sunburn prevalence among adults in the United States, 1999. Am J Prev Med 2002;23:91–7.
- 4. Cockburn MG, Zadnick J, Deapen D. Developing epidemic of melanoma in the Hispanic population of California. Cancer 2006;106: 1162–8.
- Gloster HM, Neal K. Skin cancer in skin of color. J Am Acad Dermatol 2006;55:741–60.
- Davis KJ, Cokkinides VE, Weinstock MA, O'Connell MC, Wingo PA. Summer sunburn and sun exposure among US youths ages 11 to 18: national prevalence and associated factors. Pediatrics 2002;110:27–35.
- Abroms L, Jorgensen CM, Southwell BG, Geller AC, Emmons KM. Gender differences in young adults' beliefs about sunscreen use. Health Educ Behav 2003;30:29–43.
- 8. Jemal A, Devesa SS, Fears TR, Hartge P. Cancer surveillance series: changing patterns of cutaneous malignant melanoma mortality rates among whites in the United States. J Natl Cancer Inst 2000;92:811–8.
- 9. Hillhouse J, Turrisi R. Skin cancer risk behaviors: a conceptual framework for complex behavioral change. Arch Dermatol 2005;141: 1028–31.
- 10. CDC. Guide to community preventive services. Atlanta, GA: US Department of Health and Human Services, CDC; 2003. Available at www.thecommunityguide.org/cancer.

FIGURE. Estimated percentage of white\* respondents aged  $\geq$ 18 years who reported having had at least one sunburn during the preceding year, by state/area — Behavioral Risk Factor Surveillance System, 1999, 2003, and 2004<sup>†</sup>

## Characteristics and Health of Caregivers and Care Recipients — North Carolina, 2005

Approximately 53.4 million caregivers in the United States provide an estimated \$257-\$389 billion worth of unpaid care annually to persons of all ages with disabilities and chronic illness (1,2). The health of caregivers and their ability to continue their contributions have emerged as public health concerns (3). A 2004 study indicated that those persons who provided the most intense caregiving reported substantially poorer health than noncaregivers or those with modest caregiving responsibilities (2). A Healthy People 2010 objective calls for public health surveillance and health promotion programs for persons with disabilities and caregivers in every state and the District of Columbia (objective 6-13) (4). Although limited caregiver surveys have provided data at the national level, data have not been available at the state level to characterize the health of caregivers or health effects of caregiving. Such information could be useful to states for planning and policy decisions and the development and implementation of interventions to promote caregivers' health. To analyze the characteristics and health of caregivers and care recipients and to assess the effects of caregiving, data were analyzed from a caregiver module that was piloted in North Carolina in the 2005 Behavioral Risk Factor Surveillance System (BRFSS) survey. This report summarizes the results of that analysis, which determined that caregivers provided an average of 20.1 hours of care per week, and 72.2% of caregivers lived in the same household as (24.9%) or within 20 minutes of (47.3%) the care recipient. Caregivers were more likely to be women (59.5%) than men and averaged more days when their mental health was not good when compared with noncaregivers (4.3 days versus 3.0 days, of the preceding 30 days). Public health initiatives should be designed to promote the health and well-being of both care recipients and caregivers.

BRFSS is a state-based, random-digit-dialed telephone survey of the noninstitutionalized, U.S. civilian population aged  $\geq$ 18 years. Questions related to caregiving were administered as part of the national BRFSS core survey (i.e., the survey questions administered in all states) in 2000 (5) but were not repeated. To improve caregiver surveillance, CDC provided funds to the University of Florida in 2004 to develop a caregiver module to collect data on the characteristics and health of caregivers. Module development was based on previous research (2) and influenced by key national stakeholders convened by AARP (formerly known as the American Association of Retired Persons) in February 2005. North Carolina was selected as the site for piloting the module because of the state's large BRFSS sample size and administrative capacity.

The following caregiver screening question was administered in the North Carolina 2005 BRFSS survey: "People may provide regular care or assistance to someone who has a longterm illness or disability. During the past month, did you provide any such care or assistance to a family member or friend?" Persons who responded "yes" to the question were classified as caregivers and completed the caregiver module by responding to questions about themselves and their primary care recipient. If the caregiver had more than one care recipient, the caregiver was asked to answer module questions in reference to the recipient who required the most care. Questions in the caregiver module related to the age and sex of the care recipient; relationship of the care recipient to the caregiver (e.g., parent, spouse, or child); care recipient's major diagnosis (e.g., heart disease, cancer, stroke, or diabetes); care recipient's functional limitations (e.g., moving around or self-care) as defined by the International Classification of Functioning, Disability, and Health (6); duration of caregiving; hours per week of caregiving; difficulties for the caregiver that were created by caregiving (e.g., stress, lack of time, and health problems); and travel time to reach the care recipient. Comparisons were tested using t tests for differences in means of continuous variables and chi-square or chi-square for trend tests among categorical variables.

Among the 5,859 survey respondents interviewed during May–August 2005, a total of 895 (weighted prevalence: 15.5%; 95% confidence interval [CI] = 14.2%–16.9%) indicated they were caregivers. A greater percentage of caregivers (59.5%) were women than men (40.5%) (Table 1). A greater percentage of caregivers (21.2%) than noncaregivers (15.8%) were non-Hispanic blacks, but a smaller percentage of caregivers (2.3%) than noncaregivers (10.3%) were Hispanic (Table 1). On average, caregivers reported more days (4.3 days out of 30 days) that their mental health was not good than noncaregivers (3.0 days), although the number of days that physical health was reported not good was similar for caregivers (3.2 days) and noncaregivers (3.5 days).

Most care recipients (67.2%) were female and older than the general population; 64.3% of care recipients were aged  $\geq$ 65 years, and 82.8% were cared for by a relative (Table 2). The major diagnoses of care recipients specified by caregivers were heart disease (12.8%), cancer (11.7%), stroke (9.1%), diabetes (9.0%), dementia (8.8%), arthritis/rheumatism (5.1%), lung disease/emphysema (3.0%), cerebral palsy (2.6%), and hypertension (2.4%). When asked to identify the functional limitations of their care recipients that required the most help, caregivers named moving around (41.7%); selfcare (e.g., eating, dressing, bathing, and toileting) (41.0%); learning, memory, and confusion (17.0%); and anxiety or depression (16.4%) (Table 2). On average, caregivers had pro-

TABLE 1. Characteristics of caregivers compared with
noncaregivers* - Behavioral Risk Factor Surveillance System,
North Carolina. 2005

	C (	aregiver n = 895)	No (r	ncaregiver n = 4,964)
Characteristic	%	(95% CI <sup>†</sup> )	%	(95% CI)
Age group (yrs)				
18–34	26.9	(21.8-32.8)	32.1	(29.7–33.9)
35–44	19.3	(16.2-22.9)	21.0	(19.6-22.6)
45–54	21.4	(18.2–24.9)	17.0	(15.7–18.4)
55–64	17.4	(14.7–20.6)	13.1	(12.4–14.5)
<u>&gt;</u> 65	15.0	(12.5–17.8)	16.7	(15.6–17.9)
Race/Ethnicity				
White, non-Hispanic	71.5	(66.1–76.3)	69.6	(68.4–72.2)
Black, non-Hispanic <sup>§</sup>	21.2	(16.6–26.6)	15.8	(13.8–16.4)
Other, non-Hispanic	5.0	(3.1–8.0)	4.2	( 3.5–5.0)
Hispanic <sup>§</sup>	2.3	(1.4–3.9)	10.3	(8.9–12.2)
Sex				
Men	40.5	(35.6–45.7)	48.8	(45.8–50.7)
Women <sup>§</sup>	59.5	(54.3–64.4)	51.1	(49.3–53.2)
Marital status				
Married/Coupled	64.8	(59.6–69.7)	63.9	(62.4–66.2)
Divorced/Separated	11.2	(9.2–13.6)	11.7	(10.6–12.6)
Widowed	5.1	(3.8–6.9)	7.1	(6.4–7.8)
Never married	18.8	(14.0–24.8)	17.3	(15.3–19.0)
Education <sup>¶</sup>				
No formal/Eighth grade				
or less	2.9	(1.6–5.2)	7.4	(6.2–8.7)
Some high school	9.9	(6.2–15.5)	10.4	(9.1–11.6)
High school graduate	28.3	(24.4–32.6)	29.3	(27.4–31.0)
Beyond high school	58.8	(53.8–63.7)	52.9	(51.2–55.1)
Annual income				
<\$25,000	30.3	(26.0–35.0)	34.0	(31.8–36.0)
\$25,000–\$34,999	17.4	(14.0–21.4)	14.0	(12.6–15.5)
\$35,000-\$49,999	16.3	(11.8–22.1)	15.0	(13.8–16.5)
\$50,000-\$74,999	15.9	(13.0–19.4)	16.1	(14.8–17.7)
<u>≥</u> \$75,000	20.1	(16.7–24.0)	21.0	(19.2–22.5)

\* Percentages are weighted according to state population estimates; groupings do not all add to 100.0% because of rounding.

<sup>†</sup>Confidence interval.

§ Significant difference between caregivers and noncaregivers by chi-square test: p<0.05.

Significant difference between caregivers and noncaregivers across categories of education (rather than between education levels); p<0.05.

vided care for 42.5 months, with 26.4% providing care for >5 years (Table 3). Although caregivers averaged 20.1 hours per week of care, 13.6% provided  $\geq$ 40 hours per week. When asked to name the one or two greatest difficulties they experienced from caregiving, 29.9% of caregivers cited stress, 27.9% cited not enough time for themselves or their families, and 12.0% indicated that caregiving had created a financial burden (Table 3). In addition, 3.5% of caregivers said caregiving created or aggravated health problems. In response to a separate question, 3.7% (CI = 2.5%-5.4%) reported sustaining an injury while caregiving. Nearly half (47.3%) of caregivers lived within 20 minutes of the care recipient; 24.9% resided in the same household (Table 3).

TABLE 2. Characteristics of care recipients\* — Behavioral **Risk Factor Surveillance System, North Carolina, 2005** 

	Car	e recipients (n = 895)
Characteristic	%	(95% CI <sup>†</sup> )
Age group (yrs)		
0–5	1.6	(0.7–3.8)
6–17	5.5	(3.6-8.3)
18–29	3.1	(1.8-5.3)
30–49	10.5	(7.9–13.9)
50–64	15.1	(12.4–18.2)
65–74	19.2	(15.9-22.9)
75–84	25.5	(22.0-29.3)
<u>≥</u> 85	19.6	(15.2–24.8)
Sex		
Male	32.8	(28.7–37.3)
Female	67.2	(62.7–71.3)
Relationship to caregiver		
Relative other than spouse	72.0	(66.9–76.6)
Nonrelative	16.0	(11.8–21.4)
Spouse	10.8	(8.6–13.5)
Paid caregiver	1.2	(0.6–2.4)
Major diagnosis		
Heart disease	12.8	(10.3–15.8)
Cancer	11.7	(9.3–14.6)
Stroke	9.1	(6.8–12.0)
Diabetes	9.0	(6.5–12.4)
Dementia	8.8	(6.5–11.7)
Arthritis/Rheumatism	5.1	(3.6–7.3)
Lung disease/Emphysema	3.0	(1.8–4.9)
Cerebral palsy	2.6	(1.2-5.3)
Hypertension	2.4	(1.3-4.5)
Other disease or condition	35.5	(31.4–39.9)

\* Percentages are weighted according to state population estimates; groupings do not all add to 100.0% because of rounding. Confidence interval.

Reported by: B Neugaard, PhD, EM Andresen, PhD, EL DeFries, MPH, Univ of Florida. RC Talley, PhD, JE Crews, DPA, Div of Human Development and Disability, National Center on Birth Defects and Developmental Disabilities, CDC.

**Editorial Note:** These findings from the piloting of the BRFSS caregiver module reveal that an estimated 15.5% of adults in North Carolina were caregivers in 2005, compared with an estimated 21% of adults nationally, according to a study published in 2004 (2). In North Carolina, caregivers were more likely to be women than men, and one fourth of caregivers had been providing care for >5 years. Care recipients were most likely to be aged  $\geq 65$  years, and more than half had a major diagnosis of a chronic disabling condition, such as heart disease, cancer, stroke, diabetes, and dementia.

Recent data on the prevalence of disability indicated that variations occur from state to state (from 11% to 26% of the population) and persons with disabilities are likely to report overall poorer health (9). The extent to which the prevalence of caregiving mirrors these variations in disability is unknown and represents an area for future research.

TABLE 3. Characteristics of caregivers* — Behavioral Risl
Factor Surveillance System, North Carolina, 2005

	0	Caregiver (n = 895)
Characteristic	%	(95% CI <sup>†</sup> )
Duration of caregiving		
≤3 mos	22.1	(18.5–26.3)
4–12 mos	22.0	(18.6–25.8)
13–24 mos	17.6	(13.0–23.5)
25 mos–5 yrs	11.8	(9.4–14.8)
>5 yrs	26.4	(22.7–30.4)
Amount of caregiving (hrs per week)		
<u>&lt;</u> 8	52.1	(47.1–57.2)
9–19	18.1	(14.8–22.0)
20–39	16.1	(13.0–19.8)
<u>≥</u> 40	13.6	(10.9–16.9)
Greatest difficulties resulting from caregiving§		
Creates stress	29.9	(26.1–34.0)
Not enough time for self or family	27.9	(22.4-34.7)
Financial burden	12.0	(9.7-14.9)
Interferes with work	6.9	(4.9–9.7)
Affects family relationships	5.6	(4.1–7.6)
Causes or aggravates health problems	3.5	(2.4–5.0)
Creates other difficulties	4.0	(2.5–6.2)
Functional limitations for which caregiver		
provides the most help <sup>¶</sup>		
Moving around	41.7	(37.2–46.3)
Self-care (e.g., eating, dressing, bathing,		
and toileting)	41.0	(36.2–45.9)
Learning, remembering, and confusion	17.0	(14.0–20.4)
Feeling anxious or depressed	16.4	(13.6–19.6)
Communicating with others	8.7	(6.8–11.1)
Seeing or hearing	7.0	(5.2–9.4)
Getting along with others	6.1	(4.4–8.5)
Travel time to care recipient		
Same house	24.9	(21.2–29.0)
<20 min	47.3	(42.5-52.1)
20–59 min	18.4	(13.9–23.9)
1–2 hrs	2.9	(1.9-4.3)
>2 hrs	6.6	(4.9-8.9)

\* Percentages are weighted according to state population estimates; group, ings do not all add to 100.0% because of rounding.

<sup>†</sup>Confidence interval.

Sespondents were asked to name one or two.

<sup>1</sup> Respondents were asked to name the top one or two activity limitations of the care recipient as defined by the World Health Organization's *International Classification of Functioning, Disability, and Health.* Available at http://www.who.int/classifications/icf/en (6).

The intensity and duration of caregiving has the potential to affect overall health among caregivers (7,8). Programs should be developed to address both the physical and mental health needs of caregivers and to relieve some of the difficulties they report (e.g., not enough time for self or family and financial burdens). Because 29.9% of caregivers indicate that stress, which can precipitate long-term physical or mental health problems, is one of the greatest difficulties resulting from caregiving, policies and preventive support should remove or mediate stressors. Also, given that 3.7% of caregivers report

injuries, training and materials should be considered to prevent these injuries. In addition, because BRFSS data are collected only from adults aged  $\geq$ 18 years, they do not reflect younger caregivers; alternative forms of national and state assessment should be developed to analyze the health needs and caregiving patterns for populations aged <18 years.

The caregiver module should be implemented in additional states to create national and state profiles of caregiving and caregiver health effects. By adopting the caregiver module, state officials, including policy makers and program planners in services for aging populations, children and youths, and persons with disabilities, will be able to develop and monitor data-driven state plans to support caregivers and care recipients.

The findings in this report are subject to at least five limitations. First, BRFSS is a telephone-based survey and excludes households without landline telephones or with cellular telephones only. Second, data are self-reported and subject to recall bias; therefore, prevalence estimates might be underestimated or overestimated. Third, no question specifically asked whether caregivers were paid or unpaid; the 1.2% of caregivers recorded as paid represents only those who provided that information without being asked, and therefore likely underestimate the proportion of caregivers who were paid. Further research might determine whether differences exist in the characteristics of paid and unpaid caregivers and the implications of these differences. Fourth, assessment of the greatest difficulties resulting from caregiving was asked only of caregivers, and no comparison can be made between caregivers and noncaregivers with regard to these difficulties (e.g., stress and not enough time for self or family). Finally, information on the relationship between the caregiver and the care recipient was limited (i.e., spouse, relative other than spouse, nonrelative, and paid). Future surveys will more fully describe this relationship (e.g., parent, sibling, or child).

The data presented in this report are the first CDCsponsored state-level data to assess the characteristics and health of caregivers and care recipients and their caregiving situations. CDC plans to support further testing to develop an optional BRFSS caregiver module for adoption by more states in 2009. Participation by all states would enable CDC to report caregiver health status, using population-based data, for the first time nationally and by state. Additionally, states would have the surveillance results needed to create benchmarks, document and prioritize caregiver needs among their residents, and plan interventions to address those needs.

#### **Acknowledgments**

The report is based, in part, on contributions by the North Carolina BRFSS team and AARP.

- 1. Arno PS, Levine C, Memmott MM. The economic value of informal caregiving. Health Aff (Millwood) 1999;18:182–8.
- National Alliance for Caregiving and AARP. Caregiving in the U.S. Washington, DC: National Alliance for Caregiving and AARP; 2004. Available at http://www.caregiving.org/data/04finalreport.pdf.
- 3. Talley RC, Crews JE. Framing the public health of caregiving. Am J Public Health 2007;97:224–8.
- 4. US Department of Health and Human Services. Healthy people 2010 (conference ed, in 2 vols). Washington, DC: US Department of Health and Human Services; 2000. Available at http://www.health.gov/healthy people.
- Behavioral Risk Factor Surveillance System. 2000 Behavioral Risk Factor Surveillance System questionnaire. Available at http://www.cdc. gov/brfss/technical\_infodata/surveydata/2000/qcoremod\_00.rtf.
- World Health Organization. International classification of functioning, disability and health. Geneva, Switzerland: World Health Organization; 2001. Available at http://www.who.int/classifications/icf/en.
- 7. Schulz R, Beach SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 1999;282:2215–9.
- 8. Ekwall AK, Sivberg B, Hallberg IR. Older caregivers' coping strategies and sense of coherence in relation to quality of life. J Adv Nurs 2007;57: 584–96.
- CDC. Disability and health state chartbook 2006: profiles of health for adults with disabilities. Atlanta, GA: US Department of Health and Human Services, CDC; 2006. Available at http://www.cdc.gov/ncbddd/ dh/chartbook.

## Acanthamoeba Keratitis — Multiple States, 2005–2007

On May 26, 2007, this report was posted as an MMWR Dispatch on the MMWR website (http://www.cdc.gov/mmwr).

In May 2006, the Illinois Department of Public Health (IDPH) informed CDC about a possible increase in Acanthamoeba keratitis (AK) at an ophthalmology center in Illinois during the preceding 3 years. The University of Illinois at Chicago (UIC) was investigating this possible increase. In October 2006, IDPH updated CDC about the ongoing UIC investigation. At that time, CDC informally contacted multiple ophthalmology centers in the United States to assess whether the potential increase in cases extended beyond Illinois. Responses from the ophthalmology centers were inconclusive. In January 2007, CDC initiated a retrospective survey of 22 ophthalmology centers nationwide to assess whether cases were increasing throughout the United States. In March 2007, data received from 13 centers demonstrated an increase in culture-confirmed cases of AK with wide geographic distribution. The increase in cases had begun in 2004 and continued to the present. On March 16, 2007, CDC initiated a multistate investigation to look for risk factors associated with this increase in AK cases. This report summarizes recent preliminary results of that investigation, which, indicated an association with AK in soft contact lens wearers who used Advanced Medical Optics (Santa Ana, California) Complete<sup>®</sup> MoisturePlus<sup>TM</sup> (AMOCMP) multipurpose cleaning solution. CDC and the Food and Drug Administration (FDA) are taking steps to notify the public and the medical and public health communities of this preliminary association. The manufacturer has undertaken a voluntary recall of the product.

AK, a rare but potentially blinding infection of the cornea, is caused by a ubiquitous, free-living ameba (Acanthamoeba) that is found commonly in the environment, including water (e.g., tap and recreational water), soil, sewage systems, cooling towers, and heating/ventilation/air conditioning (HVAC) systems. AK primarily affects otherwise healthy persons who wear contact lenses; an estimated 85% of U.S. cases occur in contact lens wearers (including wearers who follow recommended contact lens-care practices) (1). Persons who improperly store, handle, or disinfect their lenses (e.g., by using tap water or homemade solutions for cleaning); swim, use hot tubs, or shower while wearing lenses; come in contact with contaminated water; have minor damage to their corneas; or have previous corneal trauma are at increased risk for infection (2). Based on an analysis of cases reported to CDC during 1985–1987, the incidence of AK in the United States has been estimated at one to two cases per million contact lens users (3,4). An estimated 30 million persons in the United States wear soft contact lenses (5).

Initial case finding for this investigation was facilitated through postings on the Epidemic Information Exchange (Epi-X), on ophthalmology/optometry/infection control listservs and websites, and through queries of clinical microbiology laboratories. As of May 24, 2007, a total of 138 patients with onset of symptoms on or after January 1, 2005, and positive Acanthamoeba cultures from corneal specimens had been reported to CDC by public health authorities and ophthalmologists from 35 states and Puerto Rico. Standardized telephone interviews of patients, ophthalmologists, and primary eye-care providers are being conducted by state and local health officials and CDC. Laboratory testing of clinical specimens, contact lenses, bottles of solution, and contact lens cases received from AK patients, including typing of Acanthamoeba spp. isolates, is ongoing. An initial analysis was conducted using data from the first 46 completed patient interviews.

Among the 46 culture-confirmed patients who were interviewed, the median age was 40 years (range: 15–77 years); six (13%) were aged <18 years. Twenty-seven (59%) were female. Of the 37 of these patients for whom clinical data were available, medical therapy was unsuccessful for nine (24%), and they were required or expected to undergo corneal transplantation. Of the 46 patients, 39 (85%) wore soft contact lenses, three (7%) wore rigid lenses, and four (9%) reported no contact lens use. Among the 42 contact lens users, 16 (38%) reported swimming while wearing contact lenses and 35 (83%) reported showering while wearing contact lenses during the month before symptom onset.

Among the 39 soft contact lens users, 36 reported using one or more specific types of contact lens solution, 21 of these (58%) reported any use of AMOCMP in the month before symptom onset, 20 (56%) reported using AMOCMP as their primary solution, and 14 (39%) reported using AMOCMP as their exclusive solution. Exposure data from the 36 patients who wore soft contact lenses and used any type of contact lens solution were compared with exposure data from controls who were interviewed as part of the 2006 CDC *Fusarium* keratitis outbreak investigation (6). These controls, who were selected as geographically matched controls for the *Fusarium* keratitis cases, represented a sample of adult soft contact lens wearers from different U.S. states who were asked about product use and behaviors during March 2006 (6).

The 14 AK soft contact lens-wearing case-patients with symptom onset dates before April 1, 2006 (the period most comparable to Fusarium controls), who reported use of a single solution were compared with 115 controls from the Fusarium investigation who reported using a single solution. The results indicated that four (29%) of the 14 AK case-patients had used AMOCMP, compared with six (5%) of the 115 Fusarium controls (odds ratio: 7.3 [95% confidence interval (CI) = 1.7-30.1]). In a separate comparison, 36 soft contact lens-wearing AK case-patients with symptom onset dates before May 24, 2007, who reported use of one or more solutions were compared with 124 Fusarium controls who reported using one or more solutions. The results indicated that 21 (58%) of the 36 AK case-patients had used AMOCMP, compared with eight (6%) of the 124 Fusarium controls (odds ratio: 20.3; [CI = 7.6-53.9]). AMOCMP lot numbers were available for 10 patients who reported using the solution; no single lot number was repeated, suggesting that AMOCMP was not intrinsically contaminated. Analysis of the reported use of other brands of contact lens solution did not reveal any statistically significant associations.

The AK investigation by CDC, state and local health departments, FDA, and other partners, is continuing, and interviews of the remaining patients with culture-confirmed AK, their treating ophthalmologists, and their primary eyecare providers are ongoing. Although the results of initial analyses are preliminary, they suggest that use of AMOCMP increases the risk for AK. Additional studies will provide a more definitive assessment of the risk associated with use of AMOCMP. However, based on the preliminary findings, persons who wear soft contact lenses and who use AMOCMP should 1) stop using the product immediately and discard all remaining solution, including partially used or unopened bottles; 2) choose an alternative contact lens solution; 3) discard current lens storage container; 4) discard their current pair of soft lenses; 5) see a health-care provider if they experience any signs of eye infection, including eye pain or redness, blurred vision, sensitivity to light, sensation of something in the eye, or excessive tearing.

Contact lens users with questions regarding which solutions are best for them should consult their eye-care provider. Patients should also consult their eye-care provider if they have any of the following symptoms: eye pain or redness, blurred vision, sensitivity to light, sensation of something in the eye, and/or excessive tearing. AK symptoms, which can last several weeks to months, vary among patients. Early in the infection, symptoms can be similar to the symptoms of other more common eye infections; however, AK can result in vision loss or blindness if untreated.

All contact lens wearers should follow established guidelines to help reduce the risk for eye infections, including AK (Box). Primary-care clinicians evaluating contact lens users with symptoms of eye pain or redness, tearing, decreased visual acuity, discharge, sensitivity to light, or foreign body sensation should consider the diagnosis of AK and refer

# BOX. Guidelines for contact lens users to help reduce their risk for eye infections

- Visit your eye-care provider for regular eye examinations.
- Wear and replace contact lenses according to the schedule prescribed by your eye-care provider.
- Remove contact lenses before any activity involving contact with water, including showering, using a hot tub, or swimming.
- Wash hands with soap and water and dry before handling contact lenses.
- Clean contact lenses according to the manufacturer's guidelines and instructions from your eye-care provider.
  - Use fresh cleaning or disinfecting solution each time lenses are cleaned and stored. Never reuse or top off old solution.
  - Never use saline solution and rewetting drops to disinfect lenses. Neither solution is an effective or approved disinfectant.
- Store reusable lenses in the proper storage case.
  - Rinse storage cases with sterile contact lens solution (never use tap water) and leave open to dry after each use.
  - Replace storage cases at least once every 3 months.

patients to an ophthalmologist, if appropriate. Diagnosis of AK requires a high degree of suspicion, especially in a contact lens wearer with a recent diagnosis of another form of keratitis, such as herpes simplex virus keratitis, who is not responding to therapy. Diagnosis of AK is based on clinical presentation and isolation of organisms from corneal culture or detection of trophozoites and/or cysts on histopathology. However, a negative culture does not necessarily rule out *Acanthamoeba* infection. Confocal microscopy and polymerase chain reaction assays to detect *Acanthamoeba* can also assist with diagnosis. Early diagnosis can greatly improve treatment efficacy.

Clinicians should consider obtaining clinical specimens (e.g., corneal scrapings) for culture before initiating treatment. Clinicians or microbiology laboratories should report cases of AK to state and local health departments or directly to CDC at telephone, 770-488-7775. *Acanthamoeba* isolates should be submitted to state laboratories according to instructions provided by local and state public health laboratories. Public inquiries should be made via telephone 800-CDC-INFO. Further information regarding *Acanthamoeba* infections is available at http://www.cdc.gov/ncidod/dpd/parasites/acanthamoeba/index.htm

**Reported by:** K Bryant, J Bugante Los Angeles County Health Dept; T Chang, DVM, S Chen, MPH, J Rosenberg, MD, California Dept of Health Svcs. R Hammond, PhD, K McConnell, MPH, R Sanderson, MA, Florida Dept of Health. J Elm, MS, M Nakata, C Wakida, Hawaii Dept of Health. C Austin, DVM, J Bestudik, MG Bordson, C Conover, MD, Illinois Dept of Public Health. L Granzow, MPH, Indiana Dept of Health. A Pelletier, MD, V Rea, MPH, Maine Dept of Health and Human Svcs. A Chu, MHS, E Luckman, MPH, Maryland Dept of Health and Mental Hygiene. K Signs, DVM, Michigan Dept of Community Health. J Harper, MS, Minnesota Dept of Health. T Damrow, PhD, E Mosher, Montana Dept of Public Health and Human Svcs. K Kruger, North Dakota Dept of Health. E Saheli, MPH, Ohio Dept of Health. M Cassidy, J Hatch, Oregon Public Health Div, Dept Human Svcs. A Weltman, MD, Pennsylvania Dept of Health. EJ Garcia Rivera, MD, Y Garcia, MPH, Puerto Rico Dept of Health. MA Kainer, MD, Tennessee Dept of Health. J Archer, MS, Wisconsin Dept of Health and Family Svcs. C Joslin, OD, Univ of Illinois Chicago. P Cernoch, Methodist Hospital of Houston; D Jones MD, M Hamill MD, A Matoba MD, S Pflugfelder MD, K Wilhelmus, MD, Baylor College of Medicine, Texas. S Beavers, MD, T Chen, MD, K Christian, DVM, M Cooper, MD, D Dufficy, DVM, M Gershman, MD, M Glenshaw, PhD, A Hall, DVM, S Holzbauer, DVM, A Huang, MD, A Langer, DVM, Z Moore, MD, AS Patel, PhD, LR Carpenter, DVM, J Schaffzin, MD, J Su, MD, I Trevino, DVM, T Weiser, MD, P Wiersma, MD, S Lorick, DO, JR Verani, MD, EIS officers, CDC.

#### **Acknowledgments**

The findings in this report are based, in part, on contributions by M Bonhomme, N Pressly, M Robboy, OD, J Saviola, OD, E Woo, Food and Drug Admin. MJ Beach, PhD, C Braden, MD, S Brim, MA, D Chang, MD, F Chow, A daSilva, PhD, AJ Deokar, MPH, R Greco Kone, MPH, S Johnston, MS, AS Kusano, MS, B Park, Y Qvarnstrom, PhD, MD, S Persaud, S Roy, MD, G Visvesvara PhD, D Wagner, K Wannemuehler, MS, JS Yoder, MPH, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, CDC.

#### References

- 1. Stehr-Green JK, Bailey TM, Brandt FH, Carr JH, Bond WW, Visvesvara GS. *Acanthamoeba* keratitis in soft contact lens wearers: a case-control study. JAMA 1987;258:57–60.
- Parmar DN, Awwad ST, Petroll WM, Bowman RW, McCulley JP, Cavanagh HD. Tandem scanning confocal corneal microscopy in the diagnosis of suspected *Acanthamoeba* keratitis. Ophthalmology 2006;113:538–47.
- 3. Schaumberg DA, Snow KK, Dana MR. The epidemic of *Acanthamoeba* keratitis: where do we stand? Cornea 1998;17:3–10.
- Stehr-Green JK, Bailey TM, Visvesvara GS. The epidemiology of Acanthamoeba keratitis in the United States. Am J Ophthalmol 1989;107:331-6.
- US Environmental Protection Agency. Do you wear contact lenses? There's something you should know. Available at http://www.epa.gov/ waterscience/acanthamoeba.
- Chang DC, Grant GB, O'Donnell K, et al. Multistate outbreak of *Fusarium* keratitis associated with use of a contact lens solution. JAMA 2006;296:953–63.

# **QuickStats**

#### FROM THE NATIONAL CENTER FOR HEALTH STATISTICS

Estimated Percentage\* of Persons Who Delayed or Did Not Receive Medical Care During the Preceding Year Because of Cost, by Respondent-Assessed Health Status<sup>†</sup> — National Health Interview Survey, United States, 2005



\* Estimates are age adjusted using the 2000 projected U.S. population as the standard population and using five age groups: 0–11 years, 12–17 years, 18–44 years, 45–64 years, and ≥65 years. Estimates are based on household interviews of a sample of the civilian, noninstitutionalized U.S. population.

<sup>†</sup> Based on responses to the following questions: "During the past 12 months, has [person] delayed seeking medical care because of worry about the cost?" and "During the past 12 months was there any time when [person] needed medical care but did not get it because [person] could not afford it?" Both questions exclude dental care. Respondents were asked to answer regarding themselves and other family members living in the same household. Health status data were obtained by asking respondents to assess their own health and that of family members living in the same household as excellent, very good, good, fair, or poor.

In 2005, approximately 7% of persons (21.7 million) delayed medical care during the preceding year because of worry about the cost, and another 5% (15.2 million) did not receive needed medical care because they could not afford it. Persons whose health was assessed as fair or poor were four to five times as likely as persons whose health was assessed as excellent or very good to delay or not receive needed medical care because of cost.

**SOURCE:** Adams PF, Dey, AN, Vickerie JL. Summary health statistics for the U.S. population: National Health Inteview Survey, 2005. Vital Health Stat 2007;10(233). Available at http://www.cdc.gov/nchs/data/series/sr\_10/sr10\_233.pdf.

<sup>§ 95%</sup> confidence interval.

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending May 26, 2007 (21st Week)\*

	Current	Cum	5-year weekly	Total o	cases rep	orted for	r previou	s years			
Disease	week	2007	averaget	2006	2005	2004	2003	2002	States reporting cases during current week (No.)		
Anthrax	_	_		1			_	2			
Botulism:				•				-			
foodborne	_	2	0	20	19	16	20	28			
infant	1	28	2	98	85	87	76	69	PA (1)		
other (wound & unspecified)	2	7	0	47	31	30	33	21	WA (1), CA (1)		
Brucellosis	1	47	2	118	120	114	104	125	CA (1)		
Chancroid	_	10	1	33	17	30	54	67			
Cholera	—	_	0	8	8	5	2	2			
Cyclosporiasis§	1	24	17	136	543	171	75	156	MI (1)		
Diphtheria	—	—	—	—	—	—	1	1			
Domestic arboviral diseases <sup>§,1</sup> :			_								
California serogroup	—	_	0	63	80	112	108	164			
eastern equine	—	_	0	7	21	6	14	10			
Powassan	_	_		1	1	1		1			
St. Louis		_	0	9	13	12	41	28			
Western equine	_	_	_	_	_	_	_	_			
Ennichiosis <sup>3</sup> :	4	25	0	690	796	527	360	511	MNI (4)		
human monocytic	2	20	5	556	506	220	201	216			
human (other & unspecified)		10	2	238	112	50	321	210	NO (2)		
Haemonhilus influenzae **		15	2	200	112		44	20			
invasive disease (age <5 vrs):											
serotype b	_	5	1	24	9	19	32	34			
nonserotype b	_	33	2	140	135	135	117	144			
unknown serotype	5	106	4	218	217	177	227	153	GA (2), CO (1), UT (1), AK (1)		
Hansen disease§	_	19	2	67	87	105	95	96			
Hantavirus pulmonary syndrome§	_	6	1	37	26	24	26	19			
Hemolytic uremic syndrome, postdiarrheal§	1	37	4	284	221	200	178	216	CA (1)		
Hepatitis C viral, acute	4	248	20	806	652	713	1,102	1,835	MN (1), UT (1), WA (1), CA (1)		
HIV infection, pediatric (age <13 yrs) <sup>††</sup>	—	_	4	52	380	436	504	420			
Influenza-associated pediatric mortality <sup>§,§§</sup>	1	61	0	41	45	_	N	N	MN (1)		
Listeriosis	4	187	11	858	896	753	696	665	OH (1), KS (1), NC (1), CA (1)		
Measles	1	13	2	73	66	37	56	44	FL (1)		
Meningococcal disease, invasive***:			_								
A, C, Y, & W-135	3	107	5	272	297	_	_	_	CT (1), OK (1), CO (1)		
serogroup B	_	41	3	170	150	_	_	_			
unknown sorogroup	12	200	15	692	27	_	_	_			
Mumps	7	384	59	6 585	314	258	231	270	OH(1) MN(1) KS(1) NC(1) GA(1) FL(1) OK(1)		
Novel influenza A virus infections	_	-00		0,000 N	N	200 N	N	270 N			
Plaque	_	_	0	17	8	3	1	2			
Poliomyelitis, paralytic	_	_	_	_	1	_	_	_			
Poliovirus infection, nonparalytic§	_	_	_	Ν	N	Ν	N	Ν			
Psittacosis§	_	3	0	19	16	12	12	18			
Q fever <sup>§</sup>	1	66	3	176	136	70	71	61	MO (1)		
Rabies, human	—	_	_	3	2	7	2	3			
Rubella <sup>†††</sup>	—	8	0	12	11	10	7	18			
Rubella, congenital syndrome	—	—	—	1	1	—	1	1			
SARS-CoV <sup>8,889</sup>	—	_	0	_	_	_	8	N			
Smallpox <sup>®</sup>	_	_	_								
Streptococcal toxic-shock syndrome <sup>s</sup>	2	34	3	125	129	132	161	118	OH (1), KY (1)		
Syphilis, congenital (age <1 yr)	3	74	8	379	329	353	413	412	NC (2), WA (1)		
Tetanus	I	20	1	38	27	34	120	25	MO (1)		
Trichipallacia	_	30	2	90	90	95	133	109			
Tularomia		6	0	13	154	124	120	00			
Typhoid fever	ے 1	101	5	333	324	322	356	321	CA(1)		
Vancomycin-intermediate Stanbylococcus aure	۹µs <sup>6</sup> —	3	_	6	2		N	N			
Vancomycin-resistant Staphylococcus aureus		_	0	1	3	1	N	N			
Vibriosis (non-cholera Vibrio species infections	)§ 2	65	ŏ	Ň	Ň	N	N	N	FL (1), CA (1)		
Yellow fever	, <u> </u>	_	_	_	_	_	_	1	$\sqrt{D} = \sqrt{D}$		

Cum: Cumulative year-to-date counts. -: No reported cases. N: Not notifiable.

§

No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Incidence data for reporting years 2006 and 2007 are provisional, whereas data for 2002, 2003, 2004, and 2005 are finalized. Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf. Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. Includes both neuroinvasive and non-neuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II. ¶

Data for *H*. influenzae (all ages, all service) voltation version are available in Table II. Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly. Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. A total of 62 cases were reported for the 2006–07 flu season. ††

§§ 99 The one measles case reported for the current week was indigenous \*\*\*

Data for meningococcal disease (all serogroups) are available in Table II. No rubella cases were reported for the current week. +++

\$8\$ Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.

	Chlamydia <sup>†</sup>						Coccidioidomycosis					Cryptosporidiosis			
Reporting area	Current	Pre 52 v	vious veeks Max	Cum	Cum	Current	Pre 52 \ Med	vious weeks Max	Cum	Cum	Current	Pre 52 v	vious veeks Max	Cum	Cum
United States	8.574	19.843	25.557	368.532	405.901	108	153	658	3.228	3.520	32	71	321	966	1.068
New England Connecticut Maine <sup>§</sup> Massachusetts New Hampshire Rhode Island <sup>§</sup> Vermont <sup>§</sup>	523  387 33 72 31	665 204 47 302 38 64 20	1,357 829 73 600 69 108 45	13,254 3,286 970 6,514 756 1,378 350	12,525 3,084 862 5,997 733 1,341 508	N 	0 0 0 0 0 0 0	0 0 0 0 0 0 0	N          	    N		5 0 2 1 0 1	38 11 6 29 5 5 4	61 11 9 18 10 5 8	98 38 13 38 6 1 2
<b>Mid. Atlantic</b> New Jersey New York (Upstate) New York City Pennsylvania	483 — — 483	2,571 377 509 753 832	4,271 541 2,745 1,523 1,776	54,213 5,132 9,903 16,763 22,415	49,713 7,708 9,141 16,982 15,882	N N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	1 — — 1	10 0 3 2 3	33 1 13 10 18	118 — 43 22 53	175 9 36 53 77
<b>E.N. Central</b> Illinois Indiana Michigan Ohio Wisconsin	1,435 655  603 75 102	3,190 982 385 749 643 372	6,223 1,290 644 1,225 3,647 528	67,350 18,565 8,059 14,983 18,435 7,308	69,328 22,281 8,329 12,629 17,297 8,792	2 — 1 1 N	1 0 1 0 0	3 0 3 2 0	13 — 10 3 N	16 — 12 4 N	6  1 5	15 2 1 3 5 4	110 22 18 10 33 53	219 19 16 54 74 56	238 31 19 37 79 72
W.N. Central lowa Kansas Minnesota Missouri Nebraska <sup>§</sup> North Dakota South Dakota	57 — — — — — 57	1,188 160 148 243 434 104 28 49	1,445 238 316 314 628 185 64 84	18,686 3,106 3,178 3,744 5,220 1,991 446 1,001	24,870 3,428 3,342 5,272 8,997 2,010 757 1,064	N N     N N N N N N N N N N N N N N N	0 0 0 0 0 0 0	54 0 54 1 0 0	3 N N N N N N N N	Z Z     Z Z Z	6 2 4 	11 2 1 2 1 0 1	77 28 8 25 21 16 1 7	146 25 23 38 29 6 1 24	159 15 21 60 33 12 1 17
S. Atlantic Delaware District of Columbia Florida Georgia Maryland <sup>§</sup> North Carolina South Carolina <sup>§</sup> Virginia <sup>§</sup> West Virginia	1,399 24 97 — 479 353 432 14	3,566 69 79 921 675 392 634 425 495 55	7,072 111 161 1,187 3,822 669 1,207 2,105 685 85	56,080 1,354 2,219 3,300 7,608 6,594 12,643 11,106 10,187 1,069	77,421 1,442 1,221 19,068 13,694 8,201 14,575 8,620 9,393 1,207		0 0 0 0 0 0 0 0 0 0 0	1 0 0 0 1 0 0 0 0	1 N N 1 N N N	2 N N 2 N N N N	13 — 12 — 1 — 1 —	18 0 8 4 0 1 1 1 0	71 3 32 18 2 11 14 5 3	246 2 3 127 45 11 25 14 16 3	241 
E.S. Central Alabama <sup>§</sup> Kentucky Mississippi Tennessee <sup>§</sup>	765 70 174  521	1,409 368 130 422 531	2,044 539 691 959 700	25,713 2,079 3,118 8,916 11,600	30,823 9,833 3,810 6,998 10,182	N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	 	3 0 1 0 1	14 11 3 8 5	47 17 15 8 7	40 14 10 5 11
<b>W.S. Central</b> Arkansas <sup>§</sup> Louisiana Oklahoma Texas <sup>§</sup>	1,627 171  260 1,196	2,158 161 315 257 1,457	3,028 337 610 472 1,911	43,866 3,324 5,225 5,190 30,127	45,844 3,230 6,888 4,749 30,977	N N N	0 0 0 0	1 0 1 0 0	N N N	N N N	3  3	5 0 1 0 2	45 3 9 9 36	36 2 14 15 5	46 6 12 28
Mountain Arizona Colorado Idaho <sup>§</sup> Montana <sup>§</sup> Nevada <sup>§</sup> New Mexico <sup>§</sup> Utah Wyoming <sup>§</sup>	198 8 112 — 67 — 11	1,334 463 306 44 52 167 166 97 27	2,025 993 416 253 144 397 324 200 45	20,832 6,497 3,730 1,263 945 3,439 2,591 1,886 481	26,307 7,989 6,408 1,329 901 3,027 4,048 2,010 595	48 48 N N 	100 99 0 0 1 0 1 0	293 293 0 0 0 3 3 4 0	2,173 2,125 N N 17 7 24	2,496 2,426 N N 31 8 29 2	3 1 - 1 1 1	4 0 1 0 0 1 0 0	40 5 7 26 3 6 3 11	66 13 21 4 4 4 11 2 7	41 9 4 6 3 9 6
Pacific Alaska California Hawaii Oregon <sup>§</sup> Washington	2,087 72 1,565 — 133 317	3,362 88 2,656 105 161 344	4,362 157 3,627 130 394 621	68,538 1,730 53,759 1,994 3,818 7,237	69,070 1,672 53,745 2,337 3,915 7,401	58 N 58 N N N	53 0 53 0 0 0	311 0 311 0 0 0	1,038 N 1,038 N N N	1,006 N 1,006 N N N		1 0 0 1 0	5 1 0 1 5 0	27 — — 27 —	30 1  29 
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U 229 U	0 — 122 3	21  234 10	U U 3,041 U	U U 44 1,999 U	U U N U	0  0 0	0  0 0	U U N U	U U N U	U U N U	0  0 0	0  0 0	U U N U	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. \* Incidence data for reporting years 2006 and 2007 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. Chamydia refers to genital infections caused by *Chlamydia trachomatis*. S Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

			Giardiasi	s			Gonorrhea					Haemophilus influenzae, invasive All ages, all serotypes <sup>†</sup>			
	Previous Current 52 weeks Cum Cum				Current	Previous Current 52 weeks Cum			Cum	Current	Previous		Cum	Cum	
Reporting area	week	Med	Max	2007	2006	week	Med	Max	2007	2006	week	Med	Max	2007	2006
United States	122	310	1,477	5,088	6,068	2,958	6,865	8,969	116,556	137,450	22	47	174	948	972
New England Connecticut Maine <sup>§</sup> Massachusetts New Hampshire Rhode Island <sup>§</sup> Vermont <sup>§</sup>	  	26 5 4 12 0 0 3	67 25 14 39 9 17 12	359 86 50 157 4 22 40	563 94 33 343 2 35 56	73 61 6 2	109 43 2 46 2 10	259 204 96 8 19 5	2,098 689 41 1,090 62 196 20	2,147 779 50 1,002 95 198 23	  	3 0 2 0 0 0	18 6 4 8 3 10 1	67 20 6 36 4 1	82 17 7 49 2 2 5
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	10  _2 8	63 7 25 16 14	120 17 101 32 34	876 36 332 282 226	1,193 180 375 380 258	144 — — — 144	683 104 119 177 249	1,537 155 1,035 376 608	14,256 1,483 2,299 3,624 6,850	12,996 2,138 2,401 4,005 4,452	2  2	10 1 3 2 3	26 5 14 6 10	200 17 57 41 85	200 37 53 38 72
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	20 — — — — — — —	44 11 0 14 15 9	100 30 0 38 32 27	709 103 N 241 272 93	976 234 N 267 291 184	542 243  225 26 48	1,297 352 157 300 328 131	2,581 485 292 880 1,563 181	26,709 6,609 3,265 6,145 8,115 2,575	27,637 8,144 3,576 5,042 8,006 2,869	4 3 1	7 1 0 2 1	15 6 10 5 6 4	101 11 20 12 51 7	170 54 32 18 34 32
W.N. Central Iowa Kansas Minnesota Missouri Nebraska <sup>§</sup> North Dakota South Dakota	6 1 - 4 	22 5 3 9 2 0 1	539 16 11 514 28 9 4 6	333 70 45 12 149 32 5 20	667 88 62 279 164 36 6 32	2  -  -  -  -  - 2	385 40 43 66 195 27 2 6	516 63 89 87 269 57 6 15	5,601 695 903 1,006 2,354 512 24 107	7,465 708 922 1,216 3,958 486 43 132	1 1 	3 0 1 1 0 0	23 1 2 17 5 2 2 0	61 1 22 25 6 1	49  9 23 13 3 1 
S. Atlantic Delaware District of Columbia Florida Georgia Maryland <sup>§</sup> North Carolina South Carolina <sup>§</sup> Virginia <sup>§</sup> West Virginia	25 — 13 12 — — —	54 1 24 12 4 0 1 9 0	103 4 7 44 28 12 0 8 28 21	934 11 28 457 176 85 	872 10 23 355 213 55 	852 10 26 — 349 310 147 10	1,598 27 37 425 339 130 328 176 125 18	3,282 44 63 549 2,068 189 676 1,026 238 44	22,190 543 898 1,564 3,159 2,155 6,427 4,681 2,472 291	33,005 591 729 8,894 6,264 2,864 6,930 3,936 2,471 326	4 — 3 1 —	11 0 3 2 0 1 1 0	34 3 2 8 7 5 9 4 7 6	250 5 2 76 52 43 33 24 7 8	240 1 78 57 30 15 20 28 10
E.S. Central Alabama <sup>§</sup> Kentucky Mississippi Tennessee <sup>§</sup>	N N	9 3 0 0 5	34 22 0 0 12	163 82 N N 81	142 73 N N 69	299 36 61 202	551 170 50 158 194	879 271 268 434 240	9,277 996 1,107 3,206 3,968	12,159 4,490 1,317 2,615 3,737	 	2 0 0 0 1	9 3 1 1 6	47 10 2  35	56 12 4 5 35
<b>W.S. Central</b> Arkansas <sup>§</sup> Louisiana Oklahoma Texas <sup>§</sup>	5 3 2 N	7 3 1 2 0	53 13 6 40 0	113 50 22 41 N	59 29 1 29 N	551 65 — 84 402	941 80 193 94 560	1,490 142 366 236 938	17,584 1,582 3,169 2,026 10,807	19,564 1,793 4,093 1,722 11,956	5  - 5  -	2 0 1 0	30 2 3 27 2	49 3 4 39 3	32 2 1 27 2
Mountain Arizona Colorado Idaho <sup>§</sup> Montana <sup>§</sup> Nevada <sup>§</sup> New Mexico <sup>§</sup> Utah Wyoming <sup>§</sup>	29 3 10  7 - 9	30 3 9 3 2 2 1 6 1	67 11 26 12 11 9 6 27 4	501 68 171 39 30 43 32 106 12	552 55 182 60 26 40 23 159 7	58 3 40  14  1	281 104 67 2 3 48 30 16 2	456 220 93 20 135 64 28 5	3,886 1,338 875 84 38 808 443 276 24	5,729 1,989 1,456 82 58 1,050 669 367 58	5 3 	4 2 1 0 0 0 0 0 0	11 6 4 1 0 2 4 3 1	127 56 27 4  6 14 19 1	102 38 30 6 15 10
<b>Pacific</b> Alaska California Hawaii Oregon <sup>§</sup> Washington	27 	57 1 43 1 9 0	558 17 93 4 14 449	1,100 20 770 25 150 135	1,044 17 855 21 151 —	437 5 331  21 80	765 10 638 14 26 72	935 27 804 26 46 142	14,955 167 12,640 249 440 1,459	16,748 220 13,838 422 568 1,700	1 1 — —	2 0 0 1 0	16 2 10 2 6 5	46 5 2 39	41 4 10 8 19
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U — U	0  6 0	0  19 0	U U 69 U	U U 52 U	U U 5 U	0  6 0	4  16 3	U U 140 U	U U 130 U	U U   U	0  0 0	0  2 0	U U 1 U	U U 1 U

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

<sup>1</sup> Incidence data for reporting years 2006 and 2007 are provisional.
<sup>1</sup> Data for *H. influenzae* (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.</li>
<sup>9</sup> Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

	A Hepatitis (viral, acute), by type <sup>†</sup>											Legionellosis								
		Prev	vious						Prev	/ious										
Poporting area	Current	52 w	eeks	Cum	Cum	Current	52 w	Nex	Cum	Cum	Current	52 w	veeks	Cum	Cum					
Inited States	17	56	175	957	1.512	16	79	390	1 458	1 623	10	53	114	507	532					
New England	2	00	21	337	107	10	, 3	530	20	52	10	3	16	22	27					
Connecticut	2	2	21	24 7	107	_	2	5 5	28 14	23	1	0	9	23	27					
Maine <sup>§</sup>	_	Ō	2	_	5	_	Ō	2	1	10	_	Ō	2	_	3					
Massachusetts	—	1	.4	8	79	—	0	1	2	15	_	1	11	13	16					
New Hampshire	_	0	15	5	2	_	0	2	5		_	0	2		2					
Vermont <sup>§</sup>	_	0	2	3	2	_	0	4	э 1	4	_	0	2	о 1	1					
Mid Atlantic	2	7	18	123	130	_	0	10	173	204	_	15	57	126	1/6					
New Jersev		1	4	21	40	_	2	6	30	63	_	2	11	120	20					
New York (Upstate)	—	2	12	31	31	—	1	14	36	26	_	5	30	40	49					
New York City	_	2	10	46	44	—	2	6	37	46	—	3	24	19	20					
Pennsylvania	2	1	4	25	24	_	3	1	70	69	_	5	19	55	57					
E.N. Central	2	6 1	17	89	125	1	9	23	171	188	1	11	31	99	108					
Indiana	_	0	7	5	29	_	2	21	39 14	14	_	1	6	6	23					
Michigan	1	2	8	32	40	1	2	8	47	60	_	3	10	39	21					
Ohio	1	1	4	27	33	—	3	10	65	44	1	4	19	49	47					
Wisconsin	_	0	4	7	13	_	0	3	6	5	_	0	3	4	14					
W.N. Central	_	2	17	62	57	_	2	14	54	55	2	1	16	16	18					
lowa	—	0	3	11	4	—	0	3	9	8	_	0	3	2	2					
Kansas Minnesota	_	0	17	33	19	_	0	13	4	6	2	0	3	4	_					
Missouri	_	1	2	10	18	_	1	5	32	31		0	2	8	9					
Nebraska§	_	0	2	4	8	_	0	3	3	3	_	Ō	2	1	4					
North Dakota	_	0	0	_	_	_	0	0	_	_	_	0	0	_	_					
South Dakota	_	0	2	2	5	_	0	1	2	1	_	0	1	1	2					
S. Atlantic	2	9	28	172	204	8	21	55	386	484	2	8	24	122	124					
Delaware	_	0	5	14	8	_	0	3	6 1	21	_	0	2	1	2					
Florida	_	3	13	57	72	7	7	14	141	172	2	2	9	57	61					
Georgia	2	1	4	27	20	1	3	10	43	75	_	1	3	10	5					
Maryland <sup>§</sup>	—	1	7	26	29	—	2	7	35	76	—	2	8	24	20					
North Carolina	_	0	11	/	40	_	1	16	56	68	—	0	5	13	14					
Virginia <sup>§</sup>	_	1	5	34	22	_	2	5	29 55	20 15	_	1	4	8	14					
West Virginia	_	Ó	3	2	1	_	ō	23	20	25	_	Ö	4	3	1					
E.S. Central	_	2	7	31	52	1	6	20	102	139	1	2	9	29	23					
Alabama§	_	0	2	7	3	_	2	10	40	36	_	0	2	3	5					
Kentucky	_	0	2	5	23	1	1	3	6	34	1	1	6	13	6					
Mississippi	_	0	4	4	4	_	0	8	8	17	_	0	2	12	1					
	_	1	5	15	22		5	1 = 0	40	52	_	1		15						
W.S. Central	_	6	19	63 4	130	1	19	159	257	250	_	1	15	26	11					
Louisiana	_	0	4	8	3	_	1	5	17	11	_	0	2	1						
Oklahoma	_	0	3	3	3	1	1	41	14	1	_	0	6	—	1					
Texas§	—	5	15	48	93	—	15	108	219	211	_	1	12	24	9					
Mountain	5	5	17	127	128	2	3	9	89	58	_	2	8	31	37					
Arizona	3	3	14	104	70	—	0	5	38	4	—	0	4	10	13					
Lolorado Idaho§		0	3 1	2	21	_	0	2	15	15	_	0	2	0	5 4					
Montana <sup>§</sup>	_	Ö	3	1	4	_	Ő	Ō	_	_	_	Ő	1	1	1					
Nevada§	_	0	2	6	7	2	1	5	19	16	—	0	2	3	4					
New Mexico <sup>§</sup>	_	0	2	1	9	—	0	2	4	8	_	0	2	2	1					
Utan Wyoming§	_	0	1	2	10	_	0	4	9	9	_	0	2	6	9					
Decific	4	14	00	066	570	2	10	105	100	100	2	1	11	25	20					
Alaska	4	0	92	200	570	1	0	3	190	192		0	1	- 35	- 30					
California	4	13	40	241	543	1	8	31	146	157	2	ĩ	11	27	38					
Hawaii	_	0	2	2	6	_	0	1	—	4	_	0	0	—	_					
Oregon <sup>§</sup>	—	1	3	11	20		2	5	29	30		0	1	1	_					
vvasnington	_	U	52	10		1	U	74	19	_	1	U	2	/						
American Samoa	U	0	0	U	U	U	0	0	U	U	U	0	0	U	U					
Guam	U	_	_	U	U	U	_	_	U	U	U	_	_	U	0					
Puerto Rico	_	1	10	25	20	_	1	9	20	19	_	0	2	2	1					
U.S. Virgin Islands	U	Ó	0	Ū		U	0	Ō	Ū	ŭ	U	Ō	0	ū	Ū.					

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. \* Incidence data for reporting years 2006 and 2007 are provisional. \* Data for acute hepatitis C, viral are available in Table I. \* Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

				Malaria		Meningococcal disease, invasive <sup>†</sup> All serogroups									
Reporting area	Current	Prev 52 w	/ious /eeks Max	Cum 2007	Cum 2006	Current	Pre 52 v Med	vious veeks Max	Cum 2007	Cum 2006	Current	Pre 52 v Med	vious veeks Max	Cum 2007	Cum 2006
United States	36	255	1.116	2.221	2.729	8	23	78	295	461	16	19	79	456	551
New England Connecticut Maine <sup>§</sup> Massachusetts New Hampshire Rhode Island <sup>§</sup> Vermont <sup>§</sup>	14 14 — — —	37 9 1 1 6 0	350 227 38 112 97 93 15	139 62 18 2 46 	334 73 34 201 16 1 9		1 0 0 0 0 0	7 3 1 4 3 1 0	12 — 3 8 1 —	25 1 2 20 1 -	1 1 - - -	1 0 0 0 0 0	3 2 3 3 2 1	20 4 3 10 	22 6 2 13 — 1
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	13 — — 13	142 26 52 3 39	552 190 392 23 223	1,106 102 348 6 650	1,631 462 669 22 478	1  1	5 0 1 3	18 7 7 9 4	65 — 16 40 9	112 33 9 58 12	1  1	2 0 1 1 0	8 2 2 4 5	54 1 14 16 23	90 9 18 33 30
<b>E.N. Central</b> Illinois Indiana Michigan Ohio Wisconsin		6 1 0 1 5	162 16 3 5 5 154	25 4 1 7 3 10	254 12 2 3 15 222	2  -   2  -	3 1 0 0 0	10 6 2 2 2 3	36 10 1 7 11 7	54 20 6 8 14 6	1   1	3 0 0 1 0	8 3 4 3 3 2	61 13 14 13 15 6	85 25 10 14 24 12
W.N. Central Iowa Kansas Minnesota Missouri Nebraska <sup>§</sup> North Dakota South Dakota	7 1 6 —	5 1 0 2 0 0 0 0	188 8 3 188 3 2 0 1	63 8 7 41 7 —	75 25 1 46  3 		1 0 0 0 0 0 0 0	12 1 12 12 1 1 0 1	19 2 1 11 2 2 	20 1 14 3 - 1 1	1 — 1 — —	1 0 0 0 0 0 0	5 3 1 3 3 1 1 1	30 7 1 9 8 2 2 1	33 9 1 7 10 5 1
S. Atlantic Delaware District of Columbia Florida Georgia Maryland <sup>§</sup> North Carolina South Carolina <sup>§</sup> Virginia <sup>§</sup> West Virginia		44 8 0 0 23 0 0 7 0	134 28 7 3 1 106 4 2 36 14	808 174 6 13  478 6 5 122 4	404 148 7 8 1 213 9 3 15 	2   2 	5 0 1 1 0 0 1 0	14 1 2 4 5 4 4 2 4 1	70 2 3 17 6 20 7 1 13 13	118 3 — 19 43 20 11 4 17 1		3 0 1 0 0 0 0 0	11 1 7 3 2 6 2 2 2	65 — 25 7 14 6 7 7	95 3 
E.S. Central Alabama <sup>§</sup> Kentucky Mississippi Tennessee <sup>§</sup>	 	1 0 0 0	4 3 2 1 3	11 2  9	2 1  1	1 1 	0 0 0 0	3 2 1 1 2	12 1 3 1 7	9 4 1 2 2	 	1 0 0 0	4 2 2 4 2	25 6 4 4 11	21 4 5 3 9
<b>W.S. Central</b> Arkansas <sup>§</sup> Louisiana Oklahoma Texas <sup>§</sup>	 	1 0 0 1	6 0 1 0 6	18  2  16	5  -  - 5	 	1 0 0 1	7 2 2 3 6	13 — 11 1 1	28 1 1 2 24	1  1	1 0 0 0	13 2 4 4 9	40 5 11 11 13	35 5 5 8 17
Mountain Arizona Colorado Idaho <sup>§</sup> Montana <sup>§</sup> Nevada <sup>§</sup> New Mexico <sup>§</sup> Utah Wyoming <sup>§</sup>		0 0 0 0 0 0 0 0 0	3 1 2 1 2 1 1 1	8  _ 2 1 5  _	4 3   1 	1    1	1 0 0 0 0 0 0 0 0	6 3 1 1 1 2 0	20 4 9 1 1 5	23 7 7 1 1 7	2 1 	1 0 0 0 0 0 0 0	5 3 1 1 1 2 2	39 10 14 2 1 3 1 7	36 10 13 1 2 3 1 4 2
Pacific Alaska California Hawaii Oregon <sup>§</sup> Washington	2 2 N 	2 0 2 0 0 0	16 1 8 0 1 8	43 2 41 N 	20  20 	1 1 	3 0 2 0 0 0	45 4 6 1 3 43	48 2 33 2 8 3	72 8 56 2 6	9 	4 0 3 0 0 0	48 1 10 1 3 43	122 1 90 2 15 14	134 2 105 4 23
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U N U	0  0 0	0  0 0	U U N U	U U N U	U U   U	0  0 0	0  1 0	U U 1 U	U U   U	U U   U	0  0 0	0  1 0	  	4

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. \* Incidence data for reporting years 2006 and 2007 are provisional. \* Data for meningococcal disease, invasive caused by serogroups A, C, Y, & W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I. \* Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

			Pertussi	s			Rocky Mountain spotted fever								
		Prev	/ious				Pre	vious				Pre	vious		
Reporting area	Current	<u>52 w</u>	eeks Max	2007	Cum 2006	Current	52 v	Max	Cum 2007	Cum 2006	Current	52 v Med	Max	Cum 2007	Cum 2006
United States	67	254	1.377	2.875	5.601	30	90	168	1.357	1.990	37	23	156	272	458
New England	_	37	78	451	885	5	11	25	190	202	_	0	9	_	4
	—	2	10	18	26	5	4	14	66	51		0	0		
Maine Massachusetts	_	28	15 45	369	23 663	_	2	8	29	33 86	IN	0	1	IN	N 4
New Hampshire	_	2	21	16	84	_	1	5	14	_	_	õ	1	_	
Rhode Island <sup>†</sup>	—	0	31		21	—	0	3	15	6	—	0	9	_	—
	_	1	150	10	00	_	10	10	101	20	_	1	5	10	10
New Jersev		32	159	427 46	139	_	0	21	121	154	_	0	2	10	7
New York (Upstate)	—	19	150	258	241	—	0	0	—	—	—	0	2	—	_
New York City Pennsylvania	2	1 9	6 20	123	31 264	_	1 9	5 20	24 97	3 151	_	0	3	6 10	4
E N Central	26	/1	80	586	70/	2	1	18	31	23	_	1	9	6	10
Illinois		9	23	62	201		Ó	7	3	6	_	Ó	4	1	11
Indiana	_	2	44	11	74	1	0	2	4	2	—	0	1	1	1
Michigan Obio	25	10	39 56	109	150 268	1	0	5 12	17	15	_	0	1	1	6
Wisconsin		3	17	72	101	_	0	0		_	_	ŏ	0	_	1
W.N. Central	6	17	139	176	601	8	6	20	83	91	5	4	13	53	34
lowa	_	4	16	52	154	_	1	7	9	12	_	0	1	_	1
Kansas Minnesota	2	3	14 110	64	128 75	4	2	6	49	31	_	0	1	_	1
Missouri	4	3	10	35	167	2	1	6	8	9	5	3	12	52	30
Nebraska†	—	1	4	7	61	—	0	0	_	_	—	0	5	1	2
North Dakota South Dakota	_	0	9 4	4 14	4 12	_	0	/	6 5	6 22	_	0	0	_	_
S Atlantic	16	18	163	379	406	9	39	62	726	939	32	11	67	139	311
Delaware	_	0	1	2	2	_	0	0		_		0	3	4	7
District of Columbia	_	0	2	2	3	—	0	0		170	_	0	1	1	
Fiorida Georgia		4	18	100	87 9	_	0	24	52 46	99	_	0	4	6	9
Maryland <sup>†</sup>	_	2	7	48	74	_	5	10	93	156	_	1	6	16	15
North Carolina	15	1	112	145	77	9	11	21	197	152	32	4	61	90	254
South Carolina Virginia†	_	2	17	33 37	62 86	_	12	31	260	259	_	2	5 12	12	о 13
West Virginia	_	ō	19	7	6	_	1	8	32	43	_	ō	2	1	1
E.S. Central	_	6	24	77	112	_	4	13	60	100	_	5	27	54	58
Alabama <sup>†</sup>	—	1	17	23	25	_	0	8		33	_	1	9	12	14
Mississippi	_	0	э 9	2	17	_	0	4	<u> </u>	6 4	_	0	1	_	_
Tennessee <sup>†</sup>	_	3	11	43	55	_	2	8	52	57	_	4	22	41	44
W.S. Central	_	17	152	172	254	_	15	34	30	343	_	1	114	3	9
Arkansas <sup>†</sup>	—	2	17	36	26	—	0	5	10	15	—	0	53	—	6
Oklahoma	_	0	2	0 1	2	_	0	7	20	24	_	0	55	_	1
Texas <sup>†</sup>	_	13	134	129	218	_	14	34	_	304	_	Ō	6	3	2
Mountain	15	29	63	494	1,330	1	2	28	33	60	_	0	4	1	6
Arizona	4	6	16	125	300	—	2	10	29	48	—	0	2	—	2
Colorado Idaho <sup>†</sup>	6	1	18	135	476	_	0	24	_	_	_	0	1	1	1
Montana <sup>†</sup>	_	1	8	21	44	_	Ő	2	_	5	_	ŏ	2	_	_
Nevadat	—	0	9	3	35	—	0	1		_	—	0	0	—	_
New Mexico'	5	10	8 48	13	37	1	0	1	1	5	_	0	1	_	2
Wyoming <sup>†</sup>	_	1	8	12	31	_	0	2	1	1	_	ŏ	1	_	1
Pacific	2	25	546	113	544	5	4	13	83	78	_	0	1	_	1
Alaska	1	1	8	11	31	3	0	6	33	13	N	0	0	Ν	N
California Hawaii	_	22	225		397 51	2 N	3	12 0	50 N	63 N	N	0	0	N	N
Oregon <sup>†</sup>	_	1	11	41	65		ŏ	4		2		ŏ	1		1
Washington	1	0	376	52	—	—	0	0	—	—	Ν	0	0	Ν	Ν
American Samoa	U	0	0	U	U	U	0	0	U	U	U	0	0	U	U
C.N.M.I.	U	_	_	U	U	U	—	—	U	U	U	_	—	U	U
Puerto Rico	_	0	1	_	_	_	1	6	19	45	N	0	0	N	N
U.S. Virgin Islands	U	0	0	U	U	U	0	Ó	Ú	Ŭ	U	0	Ó	U	U

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. \* Incidence data for reporting years 2006 and 2007 are provisional. Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(		S	almonello	osis		Shiga t	oxin-pro	ducing E	. <i>coli</i> (ST	Shigellosis						
		Prev	/ious	•			Pre	vious				Pre	vious			
Reporting area	Current week	52 w Med	Max	Cum 2007	Cum 2006	Current week	Med	Max	Cum 2007	2006	Current week	Med	Max	2007	2006	
United States	277	835	1,842	10,709	11,899	25	72	295	823	793	202	268	749	4,326	3,904	
New England Connecticut Maine <sup>§</sup> Massachusetts	1 	39 0 2 24	121 107 14 87	561 107 35 335	1,142 503 33 548	 	4 0 1 2	22 9 8 13	50 9 12 21	114 75 4 30	 	4 0 0 3	21 11 5 18	74 11 8 50	191 67 2 115	
New Hampshire Rhode Island <sup>§</sup> Vermont <sup>§</sup>	1 	4 2 1	26 15 6	37 28 19	18 29 11		0 0 0	4 2 4	4 1 3	2 1 2		0 0 0	2 3 2	3 1 1	5 2	
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	11 — 1 10	96 19 28 23 31	189 50 93 45 66	1,383 54 431 368 530	1,412 278 301 387 446	 	8 1 3 0 3	61 16 14 4 47	82 1 36 8 37	99 28 33 14 24	1  1 	13 2 3 5 1	48 34 43 12 6	173 13 39 94 27	335 115 87 97 36	
<b>E.N. Central</b> Illinois Indiana Michigan Ohio Wisconsin	39 	97 29 15 18 23 17	203 65 55 35 56 32	1,428 290 195 274 397 272	1,711 486 195 301 420 309	2 1 1	9 1 1 3 2	63 8 6 18 41	99 12 10 19 42 16	118 14 14 25 34 31	17 — — 17 —	25 9 2 2 4 4	75 53 17 5 23 14	275 35 24 14 145 57	400 135 53 77 57 78	
W.N. Central Iowa Kansas Minnesota Missouri Nebraska <sup>§</sup> North Dakota South Dakota	28 	49 7 12 16 3 0 2	109 26 20 60 35 10 5 11	873 125 144 209 279 58 11 47	761 132 114 176 213 73 6 47	1    	12 2 3 3 1 0 0	45 38 4 26 13 11 0 5	120 19 12 51 23 14 	116 22 4 38 37 11 	39 — 39 — 39 —	44 2 1 5 14 1 0 6	85 14 11 24 78 14 18 24	892 20 13 93 742 7 4 13	472 16 32 30 321 32 4 37	
S. Atlantic Delaware District of Columbia Florida Georgia Maryland <sup>§</sup> North Carolina South Carolina <sup>§</sup> Virginia <sup>§</sup> West Virginia	93 — 68 19 — 6 —	227 2 1 95 29 14 29 18 20 1	403 10 4 176 76 32 130 47 58 31	2,906 29 14 1,297 423 201 444 231 229 38	2,786 27 23 1,227 403 132 453 243 245 33	4 	13 0 2 2 3 2 0 3 0	32 3 1 8 7 9 11 3 11 5	186 6 	136 1 29 23 12 28 3 40	113 — 62 51 — — —	74 0 37 25 1 1 0 2 0	150 2 5 76 62 10 14 4 9 2	1,529 4 1,006 413 25 25 23 28 1	921 	
E.S. Central Alabama <sup>§</sup> Kentucky Mississippi Tennessee <sup>§</sup>	5  - 5  -	51 11 9 12 17	139 70 23 86 32	672 199 153 86 234	669 224 119 139 187	 	4 0 1 0 2	21 5 12 3 9	37 8 12 	55 6 13 1 35	3 	12 6 2 1 3	84 66 15 71 14	323 141 41 71 70	265 67 130 31 37	
<b>W.S. Central</b> Arkansas <sup>§</sup> Louisiana Oklahoma Texas <sup>§</sup>	13 8 	84 13 14 10 44	186 45 42 103 107	410 134 120 120 36	1,038 276 138 86 538	3  -   3  -	4 1 0 2	53 7 1 17 48	49 10  11 28	41 8  4 29	8 2 6	38 2 3 2 30	245 10 24 60 174	399 41 68 28 262	489 29 9 32 419	
Mountain Arizona Colorado Idaho <sup>§</sup> Montana <sup>§</sup> Nevada <sup>§</sup> New Mexico <sup>§</sup> Utah Wyoming <sup>§</sup>	33 8 10  7  8 	50 17 12 3 2 4 4 4 4	88 44 30 9 10 20 15 14 4	843 300 233 38 31 69 56 93 23	835 244 246 48 40 54 73 105 25	4 4 — — —	8 2 1 0 0 1 2 0	34 9 8 0 5 5 14 3	104 42 19 6 	89 24 23 13 — 11 7 10 1	5 2  1 2	22 10 3 0 1 2 1 0	84 37 15 3 13 20 15 4 19	260 129 45 4 11 13 33 8 17	301 161 45 6 29 37 18 3	
<b>Pacific</b> Alaska California Hawaii Oregon <sup>§</sup> Washington	54 3 44 — 7	105 1 89 5 7 0	890 5 260 16 17 625	1,633 32 1,254 75 90 182	1,545 33 1,272 87 153 —	11 N 4 1 6	3 0 0 1 0	164 0 8 3 9 162	96 N 56 6 12 22	25 N 4 21	16   1	33 0 28 1 1 0	256 2 84 3 6 170	401 6 321 13 19 42	530 4 449 17 60	
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U U U	0  15 0	0  66 0	U U 250 U	U U 127 U	U U N U	0  0 0	0  0 0	U U N U	U U N U	U U  U	0  0 0	0  6 0	U U 11 U	U U 9 U	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. \* Incidence data for reporting years 2006 and 2007 are provisional. \* Includes *E. coli* O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

	Stre	ptococca	disease,	invasive, g	roup A	Strept					
Poparting area	Current	Prev 52 w	vious eeks	Cum	Cum	Current	Prev 52 w	vious veeks	Cum	Cum	
	44	02	247	2007	2000	week	29	102	663	647	
New England Connecticut	44 — —	93 6 0	247 28 17 2	2,251 167 35 8	2,756 220 55	9 — —	28 2 0	103 11 6 1	54 	647 77 19	
Massachusetts New Hampshire Rhode Island <sup>§</sup> Vermont <sup>§</sup>	 	4 0 0	10 9 12 2	95 18 — 11	140 6 4		2 0 0	6 4 3	42 6 3 2	57 1 —	
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	6  6	16 1 5 3 6	39 6 26 11	416 28 149 96 143	523 94 154 96 179		3 0 2 0	19 4 14 3 0	53 — 53 — N	89 31 49 9 N	
<b>E.N. Central</b> Illinois Indiana Michigan Ohio	11 	15 4 2 4 4	29 10 12 10 14	400 81 57 105 138	593 184 63 121 154		6 1 0 1 1	14 6 10 4 7	98 9 10 40 35	170 46 21 42 34	
Wisconsin <b>W.N. Central</b> Iowa Kansas	4 1	1 5 0 1	6 32 0 3	19 186  24	71 177  36	5 	0 2 0 0	2 9 0 3	4 60 1	27 52 — 11	
Minnesota Missouri Nebraska <sup>§</sup> North Dakota South Dakota	3 	0 2 0 0 0	29 6 2 2 2	86 52 11 9 4	78 32 18 6 7	5 — — —	1 0 0 0	6 3 2 1 0	40 14 4 1	25 10 4 2 —	
S. Atlantic Delaware District of Columbia Florida Georgia Maryland <sup>§</sup> North Carolina South Carolina <sup>§</sup> Virginia <sup>§</sup>	13 7 6 	20 0 5 5 4 0 1 2	48 2 3 16 11 8 26 7 11	504 3 7 127 100 89 56 45 67	531 5 7 125 135 72 67 40 66	1  1  	3 0 0 1 0 0	12 0 1 5 4 6 0 3 3	127 — 31 39 36 — 11 8	33 — — — 25 — —	
West Virginia <b>E.S. Central</b> Alabama <sup>§</sup> Kentucky Mississippi Tennessee <sup>§</sup>	 N	0 4 0 1 0 3	5 11 0 4 0 7	10 90 N 24 N 66	14 114 N 28 N 86	 		4 6 0 2 6	2 42 N  2 40	8 9 N 	
<b>W.S. Central</b> Arkansas <sup>§</sup> Louisiana Oklahoma Texas <sup>§</sup>	 	6 0 2 3	80 2 2 21 56	138 12 4 41 81	192 17 2 56 117	1 1 —	4 0 1 1	39 2 4 12 24	110 7 24 25 54	87 14 2 20 51	
Mountain Arizona Colorado Idaho <sup>§</sup> Montana <sup>§</sup> Nevada <sup>§</sup> New Mexico <sup>§</sup> Utah Wyoming <sup>§</sup>	9 2 4 N  3	11 5 3 0 0 1 1 0	23 11 9 1 0 1 6 7 1	297 117 90 6 N 2 25 54 3	364 196 58 6 N 1 67 34 2	1 1 N 	4 2 1 0 0 0 0 0	12 7 4 1 0 1 4 0 0	102 57 30 2 N 1 12 —	117 69 27 1 N  20 	
<b>Pacific</b> Alaska California Hawaii Oregon <sup>§</sup> Washington	1 1 N N N	3 0 2 0 0	9 2 0 9 0	53 15 N 38 N N	42 N N 42 N N	1 N N N	0 0 0 0 0	4 2 0 2 0 0	17 15 N 2 N N	13 — 13 N N	
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U   U	0  0 0	0  0 0	U U   U	U U  - U	U U N U	0  0 0	0  0 0	U U N U U	U U N U	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. \* Incidence data for reporting years 2006 and 2007 are provisional. Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by *S. pneumoniae*, which is susceptible or for which susceptibility testing is not available (NNDSS event code 11717). \* Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

		St	reptococc	us pneum	<i>oniae</i> , inva	sive diseas	e, drug re	esistant <sup>†</sup>	· · · · · · · · · · · · · · · · · · ·	Syphilis, primary and secondary							
		Prev				Aye <5 years					Previous						
	Current	52 w	eeks	Cum	Cum	Current	52 v	veeks	Cum	Cum	Current	52 v	/eeks	Cum	Cum		
Reporting area	week	Med	Max	2007	2006	week	Med	Max	2007	2006	week	Med	Max	2007	2006		
United States	27	46	254	1,147	1,308	2	7	31	168	163	72	183	315	3,223	3,600		
New England	_	1	12	24	73	_	0	3	4	2	4	4	13	85	76		
Connecticut	—	0	5		57	—	0	0		-	_	0	10	10	17		
Maine <sup>3</sup> Massachusetts	_	0	2	5	4	_	0	2	_	_	3	3	7	54	4		
New Hampshire	_	õ	õ	_	_	_	ŏ	õ	_	_	1	õ	2	10	5		
Rhode Islands	—	0	4	8	4	—	0	1	1	_	—	0	5	9	6		
Vermont <sup>s</sup>	_	0	2	11	8	_	0	1	2	1	_	0	1	1	2		
Mid. Atlantic	_	3	8	74	75	—	0	5	17	10	1	23	44	592	465		
New York (Upstate)	_	1	5	25	21	_	0	4	7	4	_	3	0 14	57 46	61		
New York City	_	0 0	Õ		_		Õ	0	_	_	_	15	35	396	232		
Pennsylvania	—	2	6	49	54	—	0	2	10	6	1	5	12	93	101		
E.N. Central	9	10	40	284	284	1	1	7	35	47	7	15	32	276	357		
Illinois		0	3	3	14	—	0	1	1	3	4	6	13	106	196		
Michigan	- 3	2	31	00	00 14	_	0	э 1	<u> </u>	2	1	2	5 10	46	33		
Ohio	6	5	38	214	188	1	1	5	28	29	2	4	9	82	81		
Wisconsin	N	0	0	N	N	—	0	0	—	—	—	1	4	24	16		
W.N. Central	_	1	124	88	21	_	0	15	7	1	_	5	14	54	106		
lowa	_	0	0		—	_	0	0	_	—	_	0	3	3	7		
Kansas Minnesota	_	0	10	46	_	_	0	15	2	_	_	0	3	21	10		
Missouri	_	1	6	35	21	_	Ő	2	3	1	_	2	8	21	64		
Nebraska§	_	0	1	2	—	—	0	0	_	—	_	0	2	1	2		
North Dakota	_	0	0		—	_	0	0		_	_	0	0	_	1		
		0	5	5		_	0	1	2			0	105				
S. Atlantic	18	21	59	517	691	1	3	8	/4 1	60	15	40	185	541	/8/		
District of Columbia	_	Ő	2	5	17	_	Ő	Ó	_	2	3	2	11	62	47		
Florida	14	11	29	302	312	1	2	8	66	57	_	12	23	68	293		
Georgia	4	6	21	173	295	_	0	1	_	1	—	4	153	20	91		
North Carolina	_	0	0	_	_	_	0	0	_	_	2	5 5	23	140	130		
South Carolina <sup>§</sup>	_	õ	õ	_	_	_	õ	Ő	_	_	1	1	10	43	34		
Virginia <sup>§</sup>	N	0	0	N	N	—	0	0	_	—	9	4	17	84	56		
West Virginia	_	1	17	32	67	_	0	1	/	_		0	2	3	1		
E.S. Central		2	9	73	98	_	0	3	15	16	16	14	29	294	232		
Alabama <sup>s</sup> Kentucky	IN	0	2	IN 15	23	_	0	1	1	3	2	5	7	95	32		
Mississippi	_	0	Ō			_	Ő	Ö	_	_		2	9	47	24		
Tennessee§	_	2	8	58	75	_	0	3	14	13	3	6	13	120	75		
W.S. Central	_	1	9	61	11	_	0	2	8	3	24	29	56	598	562		
Arkansas <sup>§</sup>	—	0	3	1	5	_	0	0	_	2	6	1	7	43	33		
Louisiana	_	1	3	22	6	_	0	1	2	1	- 3	6	30	126	79		
Texas <sup>§</sup>	_	Ő	0		_	_	Ő	Ō	_	_	15	21	31	398	418		
Mountain	_	1	5	26	55	_	0	5	8	24	3	8	27	107	195		
Arizona	_	Ó	Õ	_	_	_	Õ	Õ	_	_	_	2	16	29	81		
Colorado		0	0			—	0	0	_	_	_	1	5	12	34		
Idano <sup>3</sup> Montana <sup>§</sup>	N	0	0	N	N	_	0	0	_	_	_	0	1	1	2		
Nevada§	_	0	3	15	13	_	0	2	5	_	3	2	12	36	47		
New Mexico <sup>§</sup>	_	0	0			_	0	0	_		_	1	7	24	26		
Utah	_	0	5	8	24	_	0	4	2	16	_	0	2	3	4		
vvyorning <sup>3</sup>	_	0	3	3	10	_	0	1	1	0	_	0		070			
Alaska	_	0	0	_	_	_	0	0	_	_	2	38	57	676 4	820		
California	N	0	Ő	N	N	_	ő	Ő	_	_	1	35	54	614	718		
Hawaii	_	0	0	—	—	—	0	0	—	—	_	0	1	2	10		
Oregon <sup>§</sup>	N	0	0	N	N	_	0	0	_	—		0	6	8	7		
washington	IN .	0	0	IN	IN 		0	0				2	-	40	60		
American Samoa	U	0	0	U	U	U	0	1	U	U	U	0	0	U	U		
Guam	N	_	_	N	N	_	_	_	_	_		_	_	_			
Puerto Rico	Ν	0	0	Ν	Ν		0	0			4	3	11	56	61		
US Virgin lelando		0	0	11	11	11	0	0	11	11	11	0	0	11			

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. -: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

<sup>1</sup> Incidence data for reporting years 2006 and 2007 are provisional.
<sup>1</sup> Incidence data for reporting years 2006 and 2007 are provisional.
<sup>1</sup> Incidence data for reporting years 2006 and 2007 are provisional.
<sup>2</sup> Incidence data for reporting years 2006 and 2007 are provisional.
<sup>3</sup> Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

		Vario	ella (chick	(ennov)			Νου	West	Nile virus	Non-neuroinvasive <sup>§</sup>						
		Prev		(enpox)			Previous									
Reporting area	Current week	52 w	veeks Max	Cum 2007	Cum 2006	Current week	52 v	veeks Max	Cum 2007	Cum 2006	Current week	52 w	veeks Max	Cum 2007	Cum 2006	
United States	437	808	1,579	19,159	25,322	_	0	178		10	_	1	399		5	
New England	1	31	215	310	2.183	_	0	3	_	_	_	0	2	_	_	
Connecticut	_	10	76	1	865	—	0	3	—	—	—	0	1	—	—	
Maine <sup>1</sup>	_	1	17	—	146	—	0	0	_	_	_	0	0	_	_	
New Hampshire	1	6	95 43	123	63	_	0	0	_	_	_	0	0	_	_	
Rhode Island <sup>1</sup>	_	Õ	0		_	_	Õ	Õ	_	_	_	Õ	Õ	_	_	
Vermont <sup>®</sup>	—	9	66	186	333	_	0	0	—	_	_	0	0	_	_	
Mid. Atlantic	91	106	195	2,369	2,648	—	0	11	_	—	_	0	4	—	—	
New Jersey	N	0	0	N	N	—	0	2	_	_	_	0	1	—	_	
New York City		0	0			_	0	4	_	_	_	0	2	_	_	
Pennsylvania	91	106	195	2,369	2,648	—	Ō	2	_	_	_	Ō	1	_	_	
E.N. Central	208	218	568	5,637	8,885	_	0	43	_	1	_	0	33	_	_	
Illinois	_	2	11	71	69	_	0	23	_	1	_	0	23	_	_	
Indiana Miabigan		0	0	2 220	0 5 9 1	_	0	7	_	_	_	0	12	—	_	
Ohio	132	118	258 449	2,220	2,581	_	0	11	_	_	_	0	2	_	_	
Wisconsin	4	15	57	473	674	_	Õ	2	_	_	_	Õ	2	_	_	
W.N. Central	58	32	136	1.083	1.092	_	0	36	_	_	_	0	79	_	1	
lowa	N	0	0	N	N	—	0	3	—	—	_	0	4	—	1	
Kansas	4	9	52	403	215	—	0	3	_	_	—	0	3	_	_	
Minnesota Missouri	54	16	0 78	546	828	_	0	6 14	_	_	_	0	2	_	_	
Nebraska <sup>¶</sup>	N	0	0	N	N	_	0	9	_	_	_	0	38	_	_	
North Dakota	_	0	60	84	18	—	0	5	_	_	—	0	28	—	_	
South Dakota	_	1	15	50	31	_	0	7	_	_	_	0	22	—	_	
S. Atlantic	41	85	224	2,185	2,457	_	0	2	—	—	—	0	7	—	_	
Delaware	—	0	6	12	40	—	0	0	_	_	_	0	0	_	_	
Florida	19	0	89	655	N	_	0	1	_	_	_	0	0	_	_	
Georgia	N	Ō	0	N	N	_	Ō	1	_	_	_	Ō	4	_	_	
Maryland	N	0	0	N	N	—	0	2	_	—	_	0	2	_	_	
North Carolina	_	18	0 72	572	710	_	0	1	_	_	_	0	0	_	_	
Virginia <sup>1</sup>	_	19	176	331	811	_	0	Ö	_	_	_	Ő	2	_	_	
West Virginia	22	25	52	607	878	_	0	1	_	_	_	0	0	_	_	
E.S. Central	_	6	43	246	50	_	0	15	_	3	_	0	16	_	_	
Alabama <sup>1</sup>		6	43	244	50	_	0	2	_	_	—	0	0	—	—	
Kentucky	N	0	0	N	N	_	0	10	_		—	0	1	_	_	
Tennessee	N	0	0	Ň	N	_	0	4	_	_	_	0	2	_	_	
W.S. Central	1	200	979	5 749	6 340	_	0	58	_	4	_	0	26	_	2	
Arkansas <sup>1</sup>	1	9	105	178	422	_	Ő	4	_	_	_	Ő	2	_		
Louisiana	_	1	11	46	46	_	0	13	—	—	_	0	9	—	1	
Oklahoma Toxasi	—	172	0	5 5 2 5		—	0	6	_		_	0	4	_	- 1	
		172	075	3,525	3,072	_	0	50	_	4	_	0	10		1	
Arizona	37	56	129	1,558	1,667	_	0	61 Q	_	2	_	0	228	_	2	
Colorado	28	22	62	612	863	_	0	10	_	2	_	0	51	_	1	
ldaho <sup>1</sup>	N	0	0	N	N	_	0	30	_	_	_	0	157	—	1	
Montana <sup>1</sup>	—	0	26	194	N	—	0	3	_	_	—	0	8	_	_	
Nevada New Mexico	_	0	3	216	283	_	0	9	_	_	_	0	16	_	_	
Utah	9	17	73	522	491	_	Ő	8	_	_	_	Ő	17	_	_	
Wyoming <sup>1</sup>	_	0	11	13	22	_	0	7	_	_	_	0	10	—	_	
Pacific	_	0	9	22	_	_	0	15	_	_	_	0	51	_	_	
Alaska	—	0	9	22	N	—	0	0	_	—	—	0	0	_		
California Hawaii	—	0	0	—	N	—	0	15	—	—	—	0	37	—	—	
Oregon <sup>¶</sup>	N	0	0	N	N	_	0	2	_	_	_	0	14	_	_	
Washington	N	õ	Õ	N	N	_	õ	ō	—	_	_	õ	2	_	_	
American Samoa	U	0	0	U	U	U	0	0	U	U	U	0	0	U	U	
C.N.M.I.	Ū	_	_	Ū	Ū	Ū	_	_	Ū	Ū	Ū	_	_	Ū	Ũ	
Guam Buarta Biac	-	10				—	_	_	—	—	—	_	_	—	_	
US Virgin Islands	1	12	20	305	247 U		0	0	<u> </u>	U		0	0	<u> </u>	<u> </u>	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. Incidence data for reporting years 2006 and 2007 are provisional. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I. Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.

#### TABLE III. Deaths in 122 U.S. cities,\* week ending May 26, 2007 (21st Week)

		All c	Il causes, by age (years)						All causes, by age (years)							
Reporting Area	All Ages	<u>≥</u> 65	45-64	25-44	1-24	<1	P&l⁺ Total	Reporting Area	All Ages	<u>&gt;</u> 65	45-64	25-44	1-24	<1	P&I <sup>†</sup> Total	
New England	521	387	95	21	8	10	47	S. Atlantic	1,077	641	273	98	36	29	60	
Boston, MA	148	106	28	7	4	3	14	Atlanta, GA	26	7	7	8	4	_	1	
Bridgeport, CT	33	24	7	1	1	_	2	Baltimore, MD	151	82	35	18	9	7	10	
Cambridge, MA	11	11	_		_	_		Charlotte, NC	112	68	29	11	2	2	13	
Hartford CT	20	18		2	_	_	5	Jacksonville, FL Miami, El	1/5	98 55	50	20	4	3	1	
Lowell MA	26	19	5		1	1	4	Norfolk VA	52	35	10	2		5	1	
Lynn MA	6	5	1	_			1	Bichmond, VA	48	29	14	4	1	_	4	
New Bedford, MA	20	16	4	_	_	_	1	Savannah, GA	40	26	11	2	1	_	1	
New Haven, CT	30	18	4	4	1	3	7	St. Petersburg, FL	57	35	12	3	4	3	3	
Providence, RI	58	50	7	_	_	1	_	Tampa, FL	201	131	48	12	4	6	15	
Somerville, MA	2	1	—	—	—	1	—	Washington, D.C.	119	69	34	11	2	3	2	
Springfield, MA	48	31	13	2	1	1	5	Wilmington, DE	11	6	3	2	_	_	1	
Waterbury, CT	23	21	2	_	—	—	2	E S Central	890	593	195	62	20	20	76	
Worcester, MA	64	45	16	3	_	_	3	Birmingham, AL	161	108	39	12		2	10	
Mid. Atlantic	1,945	1,333	432	122	34	23	100	Chattanooga, TN	85	57	20	3	2	3	6	
Albany, NY	33	17	9	4	1	2	1	Knoxville, TN	94	61	20	8	3	2	9	
Allentown, PA	27	24	1	2	—	—	2	Lexington, KY	55	39	13	1	1	1	3	
Buffalo, NY	102	69	25	6	—	2	4	Memphis, TN	180	124	38	11	2	5	23	
Camden, NJ	12	7	1	3	—	1	—	Mobile, AL	124	76	26	13	9	_	5	
Elizabeth, NJ	18	13	4	1	_	_	3	Montgomery, AL	44	31	11	2	_	_	5	
Erie, PA	45	38	7	_	_		2	Nashville, TN	147	97	28	12	3	7	15	
Jersey City, NJ	31	21	6	2	1	1	5	W.S. Central	1,226	808	280	82	25	31	70	
New York City, NY	1,011	10	235	58	17	8	39	Austin, TX	106	65	27	12	_	2	11	
Paterson NI	16	12	10	6	1	_	2	Baton Rouge, LA	45	23	16	5	_	1	1	
Philadelphia PA	245	154	60	20	6	5	11	Corpus Christi, TX	58	48	7	2	—	1	4	
Pittshurah PA§	243	20	6	1	_		3	Dallas, TX	U	U	U	U	U	U	U	
Reading, PA	35	30	3	1	1	_	2	El Paso, TX	46	28	12	4		2	2	
Rochester, NY	141	110	22	5	1	3	13	Fort Worth, IX	110	//	24	4	1	4	/	
Schenectady, NY	24	20	2	1	1	_	2	Houston, IX	368	225	90	35	11	1	8	
Scranton, PA	20	15	4	_	1	_	_	Little Rock, AR	82	54	17	3	2	6	2	
Syracuse, NY	77	54	16	4	3	_	7	San Antonio TX	200	1/2	42	12	8	5	17	
Trenton, NJ	25	13	8	2	1	1	1	Shrevenort I A	209	48	20	3		2	8	
Utica, NY	8	5	2	1	_	_	—	Tulsa, OK	129	98	25	2	3	1	10	
Yonkers, NY	15	11	4	_	_	_	_	Manutain	054	400	450	40	10		00	
E.N. Central	1,995	1,298	458	133	48	58	123	Mountain	654	422	152	48	12	20	39	
Akron, OH	51	30	16	2	2	1	1	Roise ID	49	27	12	6	1	2	2	
Canton, OH	32	24	4	3	—	1	6	Colorado Springs CO	40	57	13	4	1	2	1	
Chicago, IL	261	152	60	30	7	12	14	Denver CO	94	55	25	7	3	4	9	
Cincinnati, OH	94	51	24	9	5	5	7	Las Vegas, NV	255	159	57	24	6	9	16	
Cleveland, OH	235	164	57	8	2	4	9	Ogden, UT	30	25	4	_	_	1	4	
Columbus, OH	210	140	52	13	8	3	7	Phoenix, AZ	U	U	U	U	U	U	U	
Dayton, On Detroit MI	1/0	93	24	18	3	5	16	Pueblo, CO	36	30	6	_	_	—	3	
Evansville IN	48	33	11	1	2	1	4	Salt Like City, UT	114	69	35	7	1	2	3	
Fort Wayne, IN	55	39	10	4	2	_	1	Tucson, AZ	U	U	U	U	U	U	U	
Gary, IN	16	7	4	3	2	_	_	Pacific	1.083	786	196	59	20	22	81	
Grand Rapids, MI	42	28	12	1	1	_	3	Berkeley, CA	13	11	1	1	_	_	2	
Indianapolis, IN	206	129	40	20	7	10	10	Fresno, CA	U	U	U	U	U	U	U	
Lansing, MI	50	41	8	_	_	1	2	Glendale, CA	U	U	U	U	U	U	U	
Milwaukee, WI	102	59	26	8	3	6	8	Honolulu, HI	69	51	13	2	1	2	6	
Peoria, IL	45	37	5	1	2	_	4	Long Beach, CA	50	35	6	6	2	1	5	
Rockford, IL	53	31	17	3	—	2	6	Los Angeles, CA	U	U	U	U	U	U	U	
South Bend, IN	52	40	11	1	—	_	3	Pasadena, CA	17	12	2	2	_	1	2	
Toledo, OH	100	68	27	2	-	3	6	Portland, OR	123	85	22	/	2	1	12	
roungstown, On	02	47	12	1	1	1	Э	Sacramento, CA	142	135	38	10	1	1	17	
W.N. Central	662	420	157	42	13	30	42	San Erancisco CA	143		20	10	3 11	3	17	
Des Moines, IA	95	70	17	8	—	—	8	San Jose CA	157	116	28	6	3	⊿	6	
Duluth, MN	19	14	4		1		1	Santa Cruz CA	28	20	20	3	2	_	2	
Kansas City, KS	20	12	6	1		1	2	Seattle, WA	120	84	21	11	3	1	Ŕ	
Kansas City, MO	86	60	18	2	4	2	4	Spokane, WA	60	47	11	2	_	_	5	
Lincoln, NE	46	33	8	3	1	1	3	Tacoma. WA	122	89	25	3	3	2	5	
Minneapolis, MN	70	36	21	4	2	7	4	Tatal	40.050++	0.000	0.000	007	010	-		
Omana, NE	79	50	20	3	_	6	6		10,053**	6,688	2,238	667	216	243	638	
St. LOUIS, MO	111 70	54	33	13	3	8	9									
Wichita KS	00 00	29 62	23	7	2	5	2									

U: Unavailable.

U: Unavailable. —:No reported cases. Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. <sup>†</sup> Pneumonia and influenza.

<sup>1</sup>Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. <sup>1</sup>Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted. \*\* Total includes unknown ages.

## FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals May 26, 2007, with historical data



\* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

Notifiable Disease Data Team and 122 Cities Mortality Data TeamPatsy A. HallDeborah A. AdamsRosaline DharaWillie J. AndersonVernitta LoveLenee BlantonPearl C. Sharp

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's Internet server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/publications/mmwr. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to *www.mmwrq@cdc.gov*.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆U.S. Government Printing Office: 2007-623-038/41028 Region IV ISSN: 0149-2195